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1. ABSTRACT 
Erythropoiesis is a dynamic complex multistep process going from committed erythroid progenitors 
to erythroid precursors and circulating mature red cells. Erythroid maturation is strictly dependent 
on EPO signaling cascade. EPO physically interacts with its receptor (EPO-R), which expression is 
downregulated after the basophilic erythroblasts stage.7 Binding of EPO to EPO-R results in EPO-R 
conformational change and it requires the activation of Jak2, as primary kinase. STAT5 is a master of 
erythropoiesis and it resides in cytoplasm. In response to EPO signaling, it binds phospho-tyrosine 
(Tyr) residues in the nucleus, initiating the transcription of several genes important in terminal 
erythroid differentiation. Giving the importance of Jak2 kinase as initiator of the EPO signaling 
cascade, additional kinases, such as Lyn, a Src family kinase, has been described to participate to EPO 
pathway. Lyn is able to phosphorylate EPO-R, Jak2 itself and STAT5. The activation of EPO/Jak2 
signaling pathway is associated with production of reactive oxidative species (ROS), which are also 
generated by a large amount of iron imported into the cells during heme biosynthesis. During 
erythropoiesis, ROS might function as second messenger by modulating intracellular signaling 
pathways. Fyn, a Src kinase, has been previously reported to participate in signaling pathways in 
response to ROS in various cell types.  
Here, we explore the potential contribution of Fyn to normal and stress erythropoiesis by studying 
2-4 months-old Fyn knockout mouse strain (Fyn-/-) and C57BL/6J as wild-type controls. Fyn-/- mice 
showed a mild compensated microcytic anemia associated with signs of dyserythropoiesis. Increased 
ROS levels and Annexin-V+ cells were presented in all Fyn-/- erythroblast subpopulations compared to 
wild-type, suggesting a possible reduction in the efficiency of erythropoietin (EPO) signaling pathway 
in the absence of Fyn. Indeed, in Fyn-/- erythroblasts we observed a reduction in Tyr-phosphorylation 
state of EPO-R associated with a compensatory activation of Jak2 without major change in Lyn 
activity. A reduction in STAT5 activation resulting in down-regulation of Cish, a known direct STAT5 
target gene, was noted in Fyn-/- erythroblasts. This was paralleled by a reduction in GATA1 and 
increased HSP70 nuclear translocation compared to wild type, supporting a higher cellular pro-
oxidant environment in the absence of Fyn. Using the vitro cell forming colony unit assay, we found 
a lower CFU-E and BFU-E cells production, which once again was associated with decreased activation 
of EPO mediated cascade in the absence of Fyn. To explore the possible role of Fyn in stress 
erythropoiesis, mice were treated with recombinant EPO, phenylhydrazine (PHZ) or doxorubicin 
(Doxo). Fyn-/- mice showed a low response to EPO compared to wild-type animals and prolonged 
anemia after either PHZ or Doxo treatment with a delayed hematologic recovery compared to wild-
type mice. When we analyzed the expression of a battery of ARE-genes related to oxidative response 
such as catalase, Gpx, heme-oxygenase 1 and peroxiredoxin-2, we noted up-regulated expression of 
these genes in sorted Fyn-/- erythroblasts compared to wild-type cells. In agreement, we observed 
increased activation of the redox-sensitive transcriptional factor Nrf2 targeting ARE-genes, whose 
regulation has been previously linked to Fyn. In fact, Nrf2 is switched-off by Fyn, ubiquitylated and 
delivered to the autophagosome by the p62 cargo protein. In Fyn-/- sorted erythroblasts, we observed 
(i) accumulation of p62 in large clusters; and (ii) reduction of Nrf2-p62 complex compared to wild-
type cells. To address the question whether the perturbation of Nrf2-p62 system results in 
impairment of autophagy in the absence of Fyn, we used LysoTracker to explore late phases of 
autophagy. Lysosomal progression was defective in Fyn-/- reticulocytes and it was associated with 
accumulation of p62 during in vitro reticulocyte maturation. These data indicate that the absence of 
Fyn blocks the Nrf2 post-induction response to oxidation, resulting in impaired autophagy. To 
validate our working hypothesis, we treated Fyn-/- mice with Rapamycin, an inducer of autophagy. In 
Fyn-/- mice, Rapamycin treatment resulted in decrease dyserythropoiesis, ROS levels and Annexin V+ 
cells, associated with reduction in accumulation of p62 in Fyn-/- erythroblasts. Collectively, our data 
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enabled us to document a novel role for Fyn in erythropoiesis, contributing to EPO-R activation and 
harmonizing the Nrf2-p62 adaptive cellular response against oxidation. 
Future studies will be designed to further characterize the signaling pathways intersects by Fyn in 
normal and diseased erythropoiesis.   
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2. ABBREVIATIONS 
 
ALA: δ aminolevulinic acid 
ALAS: δ aminolevulinic acid synthase 
AMPK: AMP activated protein kinase 
ARE: antioxidant responsive element 
Atg 3: autophagy related protein 3 
Atg 4: autophagy related protein 4 
Atg 5: autophagy related protein 5 
Atg 7: autophagy related protein 7 
Atg 10: autophagy related protein 10 
Atg 12: autophagy related protein 12 
Atg 14: autophagy related protein 14 
Atg 16: autophagy related protein 16 
Atg 101: autophagy related protein 101 
BFU-E: burst forming unit-erythroid 
BMMC: bone marrow derived mast cell 
BMPR: bone morphogenetic protein receptor 
β-thal: β-thalassemia 
CFU-E: colony forming unit erythroid 
CML: chronic myelogenous leukemia 
CPgenIII: coproporphynogen III 
DOXO: doxorubicin 
EKLF: erythroid Kruppel like factor 
EPO: erythropoietin 
EPO-R: erythropoietin receptor 
ERFE: erythroferrone 
ERK: extracellular signal regulated kinase 
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FECH: ferrochelatase 
FIP200: FAK family interacting protein of 200 KDa 
FOXO 3a: forkhead box 0 3a 
Fpn: ferroportin 
GAPDH: glyceraldehyde 3-phosphate dehydrogenase 
G6PD: glucose-6-phosphate dehydrogenase 
Hamp: hepcidin 
HBB: hemoglobin B 
HBA: hemoglobin A 
HistH3: histone H3 
HO-1: heme oxygenase 1 
Hp: haptoglobin 
HSC: hematopoietic stem cell 
HSP70: heat shock protein 70 
hVps34: class III phosphoinositide 3 kinase 
IL-6: interleukin 6 
IRE: iron responsive element 
IRP: iron responsive protein 
Keap1: Kelch like ECH associated protein 1 
KIR: Keap1 interacting region 
LC3: microtubule associated protein 1A/1B light chain 
LDH: lactate dehydrogenase 
LIR: LC3 interacting region 
mTOR: mammalian target of rapamycin 
NAC: N-acetyl cysteine 
NQO1: NADPH dehydrogenase quinone 1 
Nrf2: nuclear factor (erythroid derived 2) like 2 
P: phospho 
Pop I: pro-erythroblasts 
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Pop II: basophilic erythroblasts 
Pop III: polychromatic erythroblasts 
Pop IV: orthochromatic erythroblasts 
PHZ: phenylhydrazine 
PPIX: protoporphyrin IX 
Prx 1: peroxiredoxin 1 
Prx 2: peroxiredoxin 2 
PV: polycythemia vera 
Rapa: rapamycin 
RBC: red blood cell 
ROS: reactive oxygen species 
SFK: src family kinase  
SH1: src homology 1 
SH2: src homology 2 
SH3: src homology 3 
SOD-1: superoxide dismutase 1 
TB: total bilirubin 
Tyr: tyrosine 
TMPRSS6: transmembrane protease serine 6 
TPO: thrombopoietin 
ULK 1: UNC 51 like kinases 1 
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3. INTRODUCTION 
 
          3.1 Erythropoiesis 
Erythrocytes transport and exchange O2/CO2, participating to key processes in cellular 
homeostasis and tissue function(s). In the peripheral circulation, red cells survive 120 
days, based on their ability to go through the narrow capillaries on microcirculation 
system. Aged erythrocytes (i.e.: red cell membrane oxidation, lipid peroxidation) are 
efficiently removed by macrophages mainly localized in spleen. Thus, erythropoiesis 
plays a crucial role to ensure the constant renewal of erythroid population.1 
During development, a first wave of erythropoiesis, described as primitive 
erythropoiesis, begins in the yolk sac, characterized by large and nucleated cells. 
Subsequently, definitive erythropoiesis, in the developing fetal liver, produces small-
enucleated cells, which will then occur in the bone marrow of adult.1 
 Erythropoiesis is a dynamic complex multistep process going from committed 
erythroid progenitors to erythroid precursors and circulating mature red cells (Fig. 1).2  
 
 
Fig. 1: The process of erythropoiesis  
(modified from Palis J. Primitive and definitive erythropoiesis in mammals. Front. Physiol. 2014; 5:3) 
 
 
Erythropoiesis is divided into 3 phases: early erythropoiesis, late erythropoiesis, 
corresponding to terminal erythroid differentiation, and reticulocyte maturation. Early 
erythropoiesis refers to the process by which multi-potential hematopoietic stem cells 
(HSC) proliferate and differentiate into committed erythroid progenitors.2 The first 
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erythroid-specific progenitor is the burst forming unit-erythroid (BFU-E), through 
processes influenced by several multipotent cytokines, such as IL-3 or SCF. The BFU-Es 
expand and develop into erythropoietin (EPO)-responsive colony forming unit-
erythroid (CFU-E), which further expand and differentiate into pro-erythroblasts.3 
Terminal erythroid differentiation begins with morphologically recognizable pro-
erythroblasts, which subsequently undergo sequential mitoses to become basophilic, 
polychromatic, and orthochromatic erythroblasts that enucleate to become 
reticulocytes. During terminal erythroid differentiation, several changes occur, 
including decrease in cell size, hemoglobinization, increased chromatin condensation, 
and enucleation. In addition, terminal differentiation is also accompanied by dramatic 
changes in the expression, as well as assembly, of membrane proteins.3-5 
Erythroid maturation is strictly dependent on EPO signaling cascade.5-6 EPO physically 
interacts with its receptor (EPO-R), which expression is downregulated after the 
basophilic erythroblasts stage.7 Binding of EPO to EPO-R results in EPO-R 
conformational change and it requires the activation of Jak2, as primary kinase. Jak2 
phosphorylates EPO-R, resulting in activation of multiple signaling pathways such as (I) 
the STAT5-BclXL system, involved in maturation and survival of erythroid precursors; 
and (II) the PI3-Kinase/Akt pathway,8-10 promoting both anti-apoptotic and 
proliferation signals.4 
STAT5 is a master of erythropoiesis and it resides in cytoplasm. In response to EPO 
signaling, it binds phospho-tyrosine (Tyr) residues (Y343) on EPO-R cytoplasmic tail. 
STAT5 is then Tyr-phosphorylated and it translocates into the nucleus, initiating the 
transcription of several genes important in terminal erythroid differentiation.11-14 This 
includes genes involved in suppression of cytokine signaling (Cish and Socs3) or in 
epigenetic regulation (Suv420h2).15-16 
Recent studies have shown that mice genetically lacking STAT5 develop anemia, due 
to ineffective erythropoiesis, associated with a blunted response to erythropoietic 
stress. A reduction in Bcl-XL expression has been documented in STAT5-/- mice, leading 
to decrease survival of early stage erythroblasts, further supporting the important role 
of STAT5 in normal and stress erythropoiesis.11-14 
Abnormalities in Jak2/STAT5 signaling pathway have been described in pathologic 
erythropoiesis such as β-thalassemia (β-thal) or Polycytemia Vera (PV).17 
10 
 
β-thal is an inherited red cell disorder characterized by reduced or absent production 
of β-globin chains. Ineffective erythropoiesis is one of the hallmarks of β-thal, 
characterized by (i) block in cell differentiation and expansion of erythroid precursors; 
(ii) severe oxidation mainly due to accumulation of free alpha chains; (iii) apoptosis of 
polychromatophilic erythroblasts. Extramedullary erythropoiesis and iron overload are 
additional elements related to the ineffective erythropoiesis, contributing to clinical 
severity of β-thal.18-20 Increased activation of Jak2/STAT5 axis has been shown in β-
thal. Evidences in a mouse model for β-thal suggest Jak2/STAT5 axis as possible 
therapeutic target in β-thal. Ongoing phase II trial with ruxolitinib (NCT02049450), a 
Jak2 inhibitor, in regularly transfused β-thal patients has shown promising results in 
reducing extramedullary erythropoiesis and splenomegaly.21 
Giving the importance of Jak2 kinase as initiator of the EPO signaling cascade, 
additional kinases, such as Lyn, a Src family kinase, has been described to participate 
to EPO pathway. Lyn is able to phosphorylate EPO-R, Jak2 itself and STAT5 (see also 
section 1.2.1).4,22 
The activation of EPO/Jak2 signaling pathway is associated with production of reactive 
oxidative species (ROS), which are also generated by a large amount of iron imported 
into the cells during heme biosynthesis.23 In erythropoiesis, ROS may function as 
second messenger through the transient oxidation of cysteine residues on signaling 
targets, further contributing to increase the complexity of signal transduction in 
response to EPO. To ensure cell survival, proliferation and differentiation, the control 
of oxidative stress is crucial during erythropoiesis. This is supported by abnormalities 
of erythropoiesis reported in mice genetically lacking antioxidant or cytoprotective 
systems, such as Peroxiredoxin 2 (Prx2) or Superoxide Dismutase 1 (SOD1).24-25 In β-
thal mice, our group has recently shown the importance of the interplay between Prx2 
and the redox-sensitive transcription factor, Nrf2 (Nuclear factor (erythroid-derived 2)-
like 2) in supporting β-thal pathologic erythropoiesis.24 
In response to oxidation, Nrf2 binds the Antioxidant Response Element (ARE) region of 
genes encoding for anti-oxidant or cytoprotective systems, such as heme oxygenase 
(HO-1), NADPH dehydrogenase quinone 1 (NQO1) or Prxs.26 
Studies in β-thal erythropoiesis have highlighted the importance of another redox-
related transcriptional factor: FOXO3a.27-28 FOXO3a belongs to the Forkhead Box O 
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(FoxO) family of transcription factors and responds to oxidative stress by the 
upregulation of ROS scavenging enzymes such as Superoxide Dismutase 2 (SOD2) or 
catalase.28 Mice genetically lacking FOXO3a are extremely sensitive to exogenous 
oxidative stress, such as that induced by phenylhydrazine (PHZ).28 
Collectively, these studies indicate the importance of the modulation of intracellular 
signal transduction during erythropoiesis as well as the adaptive mechanisms activated 
in response to oxidation. Although progresses have been made in characterization of 
signaling pathways and cell protective machinery during erythroid maturation, much 
still remain to be investigated in normal and pathological erythropoiesis. 
 
3.1.2 Erythropoiesis and iron homeostasis  
Iron is an essential element in cellular homeostasis and it is involved in redox controlled 
reactions, required in enzymatic cascade as well as in signal transduction pathways.29 
Since the large part of iron is required in hemoglobin synthesis, erythropoiesis deeply 
affects iron metabolism.30 Studies in both acquired and inherited disorders 
characterized by either iron-deficiency or iron-overload have highlighted new 
mechanisms involved in iron homeostasis.29-30  
 
3.1.3 Hepcidin systemic iron homeostasis  
Hepcidin (Hamp) is the master regulator of iron homeostasis. Hamp is mainly 
synthesized by hepatocytes.31 Hamp inhibits the transfer of dietary iron from duodenal 
enterocytes to plasma, the release of recycled iron from macrophages, predominantly 
in the spleen and the release of stored iron from hepatocytes.32 This cascade is related 
to the functional crosstalk between Hamp and its receptor ferroportin (Fpn), resulting 
in decreased iron release from cells to plasma and extracellular fluid.31-32 
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Fig. 2: Iron homeostasis  
(modified from Ganz T. Systemic iron homeostasis. Physiol Rev. 2013; 93:1721-41) 
 
Hamp expression is affected by: (I) iron levels or inflammation as stimulatory factors; 
(II) erythropoietin-stimulated expansion of erythroid precursors as inhibitory factor 
(Fig. 2).31 
Transferrin-bound iron concentrations contributes to regulation of Hamp expression. 
This regulatory pathway involves the bone morphogenetic protein receptor (BMPR) 
complex that signals predominantly through the SMAD4 pathway towards Hamp.31-32 
BMP6 binding to BMPR, limits further intestinal iron absorption and release of iron 
from macrophage stores. Hemojuvelin (also known as HFE2), is another iron-specific 
ligand playing a role in Hamp expression. Hemojuvelin interacts with both BMPs and 
the BMPR, and it is negatively regulated through specific proteolytic cleavage by 
transmembrane protease serine 6 (TMPRSS6; also known as matriptase 2).31-32 Finally, 
interleukin-6 (IL-6) is also involved in Hamp expression in response to inflammatory 
storm.31-32 IL-6 activates the Jak2/STAT3 pathway inducing Hamp expression. Our 
group has recently shown that the absence of Prx2 results in perturbation of IL6 
independent STAT3 activation towards Hamp expression, highlighting the novel role of 
Prx2 in iron homeostasis.33 
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Progresses in the knowledge of the functional link between iron homeostasis and 
pathologic erythropoiesis has allowed the identification of Erythroferrone (ERFE).34 
ERFE suppresses Hamp expression through a still unknown mechanism, possibly 
involving the BMP/SMAD signaling pathway.35-36 
 
3.1.4 Erythropoiesis and heme 
Heme biosynthesis is another crucial event in erythroid hemoglobinization. In all cells, 
heme synthesis occurs through 8 enzymatic reactions, divided between mitochondria 
and cytosol compartments. During erythropoiesis, heme synthesis increases with cell 
differentiation and it is tightly coordinated with iron acquisition and globin gene 
synthesis.37-40 
In heme biosynthesis, the first step is the condensation of succinyl-CoA and glycine to 
form δ-aminolevulinic acid (ALA) in mitochondrial matrix. This reaction is catalyzed by 
ALA synthase (ALAS), which is considered a rate-limiting event. There are two isoforms 
of ALAS, ALAS1 and ALAS2, which are encoded by separated genes. Alas1 gene is 
located on chromosome 3 and it is ubiquitously expressed. It plays an important 
housekeeping function in providing heme in non-erythroid tissues.37-40 Otherwise, 
Alas2 gene is located on the X-chromosome and it is expressed exclusively in erythroid 
cells. Alas2 expression strongly increases during the late stages of erythroid 
differentiation and it is essential for terminal maturation of red cells.41-42 The 
expression of Alas2 is regulated by erythroid-specific transcription factors, such as 
GATA-1.43 At post-transcriptional level, Alas2 expression is sensitive to iron 
intracellular levels. Alas2 transcript contains a 5′ iron responsive element (IRE) that 
interacts with iron responsive proteins (IRPs), linking the regulation of heme 
biosynthesis to the availability of iron in erythroid cells. 
ALA is then exported to the cytosol, where it is converted to coproporphyrinogen III 
(CPgenIII). Then, CPgenIII is imported back to mitochondria and it is converted to 
protoporphyrin IX (PPIX). Finally, ferrous iron (Fe2+) is incorporated into PPIX to form 
heme in mitochondrial matrix, a reaction catalyzed by ferrochelatase (FECH) (Fig. 3).44 
Recently, two heme exporters have been described: (I) FLVCR1a, localized in cellular 
plasma membrane; (II) FLVCR1b, localized in mitochondria plasma membrane. The 
coordinated expression of FLVCR1a and FLVCR1b contributes to control the size of the 
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cytosolic heme pool required to sustain metabolic activity during the expansion and 
hemoglobinization of erythroid cells (Fig. 3).38-40,45,46 
Fig. 3: Heme biosynthesis  
(modified from Tolosano E, et al. Heme and erythropoiesis: more than a structural role. Haematologica. 2014; 
99:973-983) 
 
 
3.2 Src family kinases (SFKs) 
Src family kinases (SFKs) are a group of cytoplasmatic Tyrosine (Tyr)-kinases, which are 
involved in signal transduction pathways important in cell homeostasis.47 SFKs 
comprises 9 members of kinases (Src, Fgr, Hck, Lyn, Yes, Lck, Fyn, Frk and Blk) some of 
which are expressed in a variety of cell types, whereas other are primarily expressed 
by hematopoietic cells, such as Lyn, Fyn or Src.48 SFKs exhibit a conserved domain 
organization that allows them to establish physical association with receptors and 
different proteins located upstream/downstream in signal cascades.48 
All family members are characterized by an N-terminal unique region (50-70 residues) 
of high variability always encompassing a myristoylation and sometimes a 
palmitoylation site, flowed by the ~ 50 amino acid Src homology 3 (SH3) domain, which 
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directs specific association with proline rich motifs related to the PXXP consensus.49-54 
This is followed by ~ 100 amino acid Src homology 2 (SH2) domain which provides the 
interaction with phosphor-Tyr motifs and confers recognition and regulatory 
proprieties. The last domain is the kinase (~ 300 residues), or catalytic domain, or Src 
homology 1 (SH1), responsible for the enzymatic activity (Fig. 4).49-54  
 
 
             
 
 
Fig. 4: Domain organization of the SFKs 
(modified by Salter MW, et al. Src kinases: a hub for NMDA receptor regulation. Nat Rev Neurosci, 2004; 5:317-328) 
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SFKs have two Tyr-motifs that regulate their activity in opposing ways. There is the 
activation loop (A-loop) residue, between the N-lobe and the C-lobe of the kinase 
domain, that is Tyr-phosphorylated in the fully active configuration, while the C-
terminal Tyr-motif is phosphorylated in the fully inactive structure.55-57 This latter can 
interact with its own SH2 domain, making phospho-Tyr tail relatively inaccessible to 
phosphatase catalysis, inactivating SFK.58 It is likely that the combined interactions of 
the SH3 and the SH2 domains stabilize the overall inactive SFK’s configuration through 
the synergic effects of the two domains. Tyr-phosphorylation of the A-loop site has 
been detected in the most highly active forms of SFKs and seems to be important for 
the maximal kinase activity possibly deleting the auto-inhibitory SH3/SH2 intra-
molecular interactions.59 This phosphorylation is likely to be mediated by a trans-
autophosphorylation, indicating that SFK members can crosstalk each other through 
the phosphorylation of the A-loop site.60 Thus, SFKs might be present as: 1) fully closed 
inactive form due to the intra-molecular SH3/SH2 interactions, a phosphorylated C-tail 
and an unphosphorylated A-loop; 2) partially active form in which the SH3 and/or SH2 
interactions are disrupted, but the A-loop is not phosphorylated; 3) fully active form 
with the A-loop phosphorylated with or without SH3/SH2 association displacement.61  
The autophosphorylation site of SFKs, plays a pivotal role when SFK is un-
phosphorylated, forming a short α-helix that prevents substrate binding and 
sequesters the A-loop Tyr. This makes the A-loop unavailable for phosphorylation, 
stabilizing the inactive kinase conformation. Otherwise, when the A-loop is 
phosphorylated, the Tyr forms a salt bridge with a conserved arginine that helps 
stabilizing the enzymatic active SFK configuration.62 
 
3.2.1 SFKs and erythropoiesis 
Among SFKs, Lyn has been recently involved in EPO signaling cascade.63,64 Lyn targets 
specific Tyr-residue on the cytoplasmic tail of Epo-R, contributing to the signaling 
events involved in erythroid maturation and differentiation.63,64 Mouse models either 
lacking Lyn (Lyn-/-) or displaying hyperactive Lyn (Lynup/up), show abnormalities in 
baseline erythropoiesis and in stress erythropoiesis .63,64 
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Table 1. Effects of the absence or hyperactivation of Lyn on immune-hematopoietic system 
Mouse strain Hematological phenotype References 
         
 
 
 
 
    Lyn-/- mice 
- Age-dependent anemia; 
- Extramedullary erythropoiesis with splenomegaly; 
- Dyserythropoiesis; 
- Increase reticulocyte count; 
- Reduced bone marrow progenitor expansion capacity 
and impaired precursors maturation/differentiation 
upon EPO stimulation; 
- Autoimmune disease related to lymphoid 
abnormalities; 
- Perturbations of myelopoiesis with age-related 
increase of myeloid progenitors. 
 
 
 
 
[64] [65] 
[66] [67]  
 
 
 
Lynup/up mice 
- Abnormal red blood morphology (acanthocytes and 
spherocyte-like cells); 
- Chronic mild hemolytic anemia; 
- Increased progenitor expansion capacity and enhanced 
precursors maturation and differentiation; 
- Extramedullary erythropoiesis; 
- Age-related bone marrow exhaustion. 
 
 
 
[68][69] 
[70] 
 
 
Studies in these mouse models have allowed the identification of signaling pathways 
intercrossed by Lyn such as, GAB2/Akt/FOXO3 acting as pro-survival system or ERK1/2 
(extracellular-signal-regulated kinase 1/2) as pro-apoptotic signal.64-67  
Lyn-/- mice show reduced STAT5 activity, which results in decreased expression of BclXL, 
a molecule with anti-apoptotic function in erythropoiesis. 64-67 
In addition, Lynup/up erythroblasts display increased proteolytically degradation of EPO-
R, suggesting an accelerated EPO-R turnover. This is associated with elevated Jak2 
activation partially independent from EPO stimulation. Increased EKLF and STAT5 
phosphorylation has been noted in Lynup/up erythroblasts, indicating possible 
downstream compensatory mechanism to constant activation of Lyn during 
erythropoiesis in this mouse strain.68-70 Finally, perturbation of Lyn function also affects 
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two master systems in erythropoiesis, GATA-1 and EKLF (Erythroid Kruppel-like 
factor).64-67 
 
          3.3 Fyn is an emerging SFK 
Fyn is another member of SFKs. Fyn is primarily localized to the cytoplasmic leaflet of 
the plasma membrane, where it phosphorylates Tyr-residues on key targets involved 
in a variety of different signaling pathways.71 This is functional to either regulate target 
proteins activity and/or generate a docking site on target proteins, allowing the 
recruitment of other signaling molecules.72 Fyn is important in cell growth and survival, 
cell adhesion, integrin-mediated signaling, cytoskeletal remodeling, cell motility, 
immune response and axon guidance.71  
The large part of available studies on mice genetically lacking Fyn are limited to 
neurobiology and brain system. 72-74 
 
3.3.1 Fyn and hematopoiesis  
In different blood cells and during hematopoiesis, recent studies have highlighted the 
role of Fyn as positive mediator of STAT5 function. In mast cell, Fyn is required for 
FcεRI-mediated STAT5 activation with possible additional role in stabilization of un-
phosphorylated STAT5.75-78 Studies on Fyn-/- bone marrow-derived mast cells (BMMCs) 
reveal abnormalities of STAT5 activation, leading to impairment of mast cells 
degranulation.75 Involvement of Fyn in STAT5 activation has been also documented in 
chronic myelogenous leukemia (CML).79 In CML, Fyn has been proposed to contribute 
to the cyclophosphamide cell resistance, suggesting Fyn as a possible new therapeutic 
target in CML.79  
F yn also participates to thrombopoietin (TPO)-induced cascade during in vitro 
megakaryopoiesis. Thus, Fyn may play a pivotal role as an additional kinase to the 
canonical TPO/Jak2 pathway in megakaryopoiesis.80-82 
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3.3.2 Fyn is a redox sensor 
In different cell types, growing evidence indicate Fyn as primary redox sensor in 
oxidation-induced signaling pathway.83-84 Fyn might act as regulatory nexus between 
oxidation and signal transduction such as in its interaction with Nrf2. In fact, Fyn has 
been involved in post-induction regulation of the redox-sensitive transcription factor 
Nrf2.85-86 In presence of a severe cellular oxidative stress, Nrf2 translocates into the 
nucleus activating the expression of acute phase defensive genes.85-86 Then, Nrf2 is 
switched-off by Fyn, which phosphorylates Tyr-568 on Nrf2, resulting in its nuclear 
export and ubiquitylation. 85-86 Mutagenesis experiments have shown that mutation of 
Tyr-213 on Fyn affects both nuclear localization and inactivation of Nrf2, increasing cell 
susceptibility to death.85-86 It has been reported that the prolonged activation of Nrf2 
results in accumulation of polyubiquitylated proteins with an imbalance between 
protein synthesis and protein degradation.87-88 In various cell types, the persistence of 
Nrf2 signaling has been shown to be linked to impaired autophagy, a main cellular 
defensive process against the accumulation of damaged proteins.89  
 
3.4 Autophagy and erythropoiesis 
3.4.1 Autophagy 
Autophagy is an efficient catabolic process responsible for the clearance of damaged 
organelles and proteins, contributing to cell homeostasis.90-93 Autophagy is generally 
activated by starvation or low levels of oxidation, whereas a more intense or prolonged 
oxidative stress overcomes autophagy flux and culminates in cell apoptosis. 94,95 
Autophagy starts with the engulfment of cellular materials by a double-layered 
structure, called the phagophore, that elongates, then closing to form the 
autophagosome. Finally, mature autophagosomes fuse with lysosomes, creating the 
autolysosome, where lysosomal hydrolytic enzymes degrade the cellular content (Fig. 
5).96  
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Fig. 5: The process of autophagy 
     (modified by Dikic I. Proteasomal and autophagic degradation systems. Annu. Rev. Biochem. 2017; 86:193-224) 
 
The core machinery of autophagy consists of autophagy-related proteins (Atg), redox-
sensitive proteins that might be either directly modulated by ROS (e.g.: Atg4 or Atg7) 
or transcriptionally regulated by oxidative stress (e.g.: p62).97-101 The functional 
connection between ROS and autophagy is also supported by the improvement of 
autophagy promoted by exogenous anti-oxidants, such as N-Acetyl-cysteine (NAC).97-
99 Ulk1 phosphorylation is considered one of the main determinants and initiator of 
autophagy.91,96 The second key complex is the Beclin1/PI3K3, whose activity is 
dependent on ULK1 phosphorylation. Beclin1/PI3K3 drives the phagophore formation, 
followed by the recruitment of ubiquitin-like Atg5-Atg12-Atg16L complex that is 
required for autophagosome formation.102 This latter, together with Atg4 and Atg7, 
can activate the microtubule-associated protein 1A/1B light chain 3 (LC3) via lipidation 
with phosphatidylethanolamine (PE) to generate LC3-II. LC3-II anchors to inner and 
outer membranes of autophagosomal structures and it is required for phagophore 
expansion and fusion.91,96,102 In addition, LC3-II recruits proteins carrying the LC3-
interacting region (LIR) to the autophagosome (Fig.6).91,103 The cargo elements are 
then directed by autophagy binding adaptor molecules, such as p62, to the terminal 
phase of autophagy.91,104 p62 is a multifunctional protein consisting of different 
ROS 
Starvation 
21 
 
domains and delivers polyubiquitinated cargoes to autophagy pathway through LIR 
domains and/or to proteasomal degradation via the N-terminal.96,104  
      
 
Fig. 6: Schematic representation of autophagy cascade 
(modified by Codogno P. Mechanisms and regulation of autophagy in mammalian cells. Atlas of Genetics and 
Cytogenetics in Oncology and Hematology,2011) 
 
                mTORC1= mammalian target of Rapamycin complex 1; AMPK= AMP-activated protein kinase; ULK1= UNC-51-like kinases 1 
                Atg13= autophagy-related protein 13; Atg101= autophagy-related protein 101; FIP200= FAK family-interacting protein of 200     
                kDa; hVps34= Class III phosphoinositide 3-kinase; Atg14= autophagy-related protein 14; Atg5= autophagy-related protein 5;   
                Atg10= autophagy-related protein 10; Atg7= autophagy-related protein 7; Atg16= autophagy-related protein 16; Atg4=   
                autophagy-related protein 4; LC3= Microtubule-associated protein 1A/1B-light chain 3 (I, cytosolic form; II, membrane bound  
                form); Atg3= autophagy-related protein 3; Atg12= autophagy-related protein 12. 
 
3.4.2 Autophagy and erythropoiesis 
In erythropoiesis, autophagy plays a pivotal role in removal of organelles, such as 
ribosomes or mitochondria (mitophagy), as well as of damaged cytosolic proteins, 
allowing the generation of mature red cells.104,105 During erythropoiesis, ROS 
generation, nutrients deprivation and activation of AMP-activated protein kinase 
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(AMPK) inhibits the mammalian target of rapamycin complex 1 (mTORC1), which is a 
key repressor of autophagy.96,105 Studies on mouse models lacking members of the 
autophagy cascade have allowed the progress in the knowledge on autophagy during 
erythropoiesis. The table below summarizes the main results on autophagy and 
erythropoiesis based on the revision of the literature. 
 
Table 2. Mouse models genetically lacking proteins related to autophagy and 
erythropoiesis 
Mouse 
strain 
Protein function Main findings Ref. 
 
 
Ulk1-/- 
mice 
 
 
Regulation of 
mitochondrial and 
ribosomal clearence 
- Reticulocytosis; 
- Increased mean cell volume (MCV), 
mean corpuscular hemoglobin 
level(MCH) and relative distribution 
width (RDW); 
- Delayed removal of mitochondria 
and ribosomes, resulting in delayed 
red cell maturation; 
- Splenomegaly; 
[105] 
[106] 
[107] 
[108] 
 
 
Atg5-/- 
mice 
 
 
Regulation of 
autophagosome 
formation 
- Decrease in hematopoietic stem cells 
proliferation; 
- Impaired cell cycle progression and 
increased apoptosis; 
- Neonatal lethality due to neuronal 
dysfunction; 
- Iron deficiency anemia; 
 
[109] 
[110] 
 
 
Atg7-/- 
mice 
 
 
Regulation of 
mitochondrial 
removal 
- Reduction in hematopoietic stem 
cells and progenitors of multiple 
lineage; 
- Impaired formation of 
autophagosomes; 
- Erythroid maturation defect; 
- Anemia and reticulocytosis; 
- -Impaired clearance of mitochondria 
[111] 
[112] 
[113] 
[114] 
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Nix-/- 
mice 
 
 
Modulation of 
mitochondrial 
clearance and 
autophagosome 
formation 
- Presence of abnormal mitochondrial 
residues; 
- Hemolytic anemia and erythroid 
hyperplasia; 
- Increased caspase activation and 
phosphatidylserine exposure leading 
to cell death and erythroid 
maturation defect; 
- -Reticulocytosis; 
- Abnormal reticulocytes maturation; 
[115] 
[116] 
[117] 
 
          3.4.3 Autophagy and Nrf2 
On steady state, Nrf2 is stabilized in the cytoplasm by Kelch-like ECH-associated protein 
1 (Keap1).118,119 Under oxidation, Nrf2 is activated, dissociated from Keap1 and it 
translocates into the nucleus. When Nrf2 function is completed, Nrf2 migrates into the 
cytoplasm to be ubiquitylated. In the meantime, p62 interacts with Keap1 through the 
Keap1-interacting region (KIR), re-directing Keap-1 towards autophagic degradation 
(Fig. 8).96,120                                           
                                        
Fig. 8: The p62-KEAP1-Nrf2 axis in stress response 
                       (modified by Zhang DD, et al. p62 links autophagy and Nrf2 signaling. FRBM, 2015;88:199-204)       
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Thus, an interplay has been established between Nrf2 degradation and autophagy.  
p62 is involved in protein quality control mechanism. It binds to the Nrf2 shuttle 
protein Keap1, participating to Keap1 turnover. Thus, accumulation of p62 might be 
used as hallmark of impaired autophagy.121 Our group has recently reported a new 
molecular link between defective autophagy in terminal erythroid differentiation in 
patients with chorea-acanthocytosis.121 Once again, the accumulation of p62 was a 
marker of repressed autophagy in this model of diseased red cell.  
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5. AIM of the study 
 
        Role of Fyn in normal and stress erythropoiesis  
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6. MATERIALS AND METHODS 
         6.1 Drugs and chemicals 
NaCl, Na3VO4, TRIS, Tween 20, EDTA, choline, MgCl2, MOPS, Na2HPO4, KH2PO4, NaF, 
bicine, β-mercaptoethanol, benzamidine, glycine, glycerol, potassium cyanide, 
bromphenol blue, sodium dodecil sulphate (SDS), hydrocortisone, albumin from 
bovine serum (BSA), May-Grunwald-Giemsa’s Azur-Eosin-Methylene Blue solution, 
were obtained by Sigma-Aldrich (Missouri, USA); dithiotreithol (DTT) was from Fluka 
(Buchs, Switzerland); protease inhibitor cocktail tablets were from Roche (Basel, 
Switzerland); 40% Acrylamide/Bis Solution, 37.5:1 was from BIO-RAD (California, USA); 
Luminata Forte Western Hrp solution was from Merck Millipore (Billerica, 
Massachusetts, USA); Prestained Protein Ladder, Triton X-100 and Temed were 
purchased from GE Healthcare Life Biosciences (Little Chalfont, UK); Annexin V Binding 
Buffer was from eBioscience (San Diego, USA); Dulbecco’s Phosphate Buffered Saline 
(DPBS) was from Lonza (Belgium); Iscove's Modified Dulbecco's Medium (IMDM), 
alpha-MEM, L-glutamine and Fetal Cow Serum (FCS) were from TermoFisher 
(Massachusetts, USA); Penicillin-Streptamicin and Amphotericin were from Euroclone 
(Milan, Italy); MethoCult™ M3234 was from StemCell Techologies (Milan, Italy). 
 
6.2 Mice strains 
We studied the following mouse strains: C57BL/6J as normal control (wild-type; WT) 
and Fyn-/- mice. Since in preliminary experiments we observed a more severe 
hematological phenotype in Fyn-/- female mice, we used female mice aging from 2 to 4 
months old. Mouse blood was collected by retro-orbital venipuncture in anesthetized 
mice using heparinized capillares according to the general guidelines of local animal 
facility, University of Verona. Whenever indicated, anemia was induced by 
intraperitoneal injection of PHZ (40 mg/Kg body weight)1or Doxorubicin (0.25 mg/Kg 
body weight).2 Blood was collected at day 2, 4, 8 and 14 from PHZ injection and at day 
3, 6 and 9 after Doxorubicin injection. Spleen and bone marrow were collected at day 
2,4,8 and 14 from PHZ injection and at day 9 after Doxorubicin injection. EPO (10 
U/mice).3 was intraperitoneally injected for 5 days. Blood was collected at day 6, 8 and 
11 after EPO administration. Rapamycin (10 mg/Kg)4 was intraperitoneally injected in 
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a single dose and spleen and bone marrow were collected after 1 week from 
Rapamycin administration.        
 
           6.3 Hematological parameters 
Hematological parameters were evaluated on Siemens ADVIA 120 Hematology 
System. Hematocrit and hemoglobin were manually determined.5,6  
 
6.4 Flow cytometric analysis of mouse erythroid precursors and cell sorting of murine 
bone marrow erythroblasts 
Cells from WT and Fyn-/- mice bone marrows and spleens were collected in BEPS (BEPS: 
PBS 1X, BSA 1%, EDTA 2 mM, NaCl 25 mM). The erythroid precursors were analyzed as 
previously described7 using CD44-Ter119 strategy. Briefly, cells were centrifuged at 
1,500 rpm for 5 min at 4°C and resuspended in the proper volume of BEPS. Cells were 
incubated first with CD16/32, to block Fc receptors, CD45-APC-Cy7, CD44-FITC, CD71-
PE and Ter119-APC (eBioscience, San Diego, USA) antibodies for 30 min at 4°C in the 
dark. Cells were washed and centrifuged at 1,500 rpm for 5 min at 4°C, resuspended 
in BEPS and 7AAD, for cell viability, was added immediately before the analysis. All the 
analysis were performed with the flow cytometer FACSCantoIITM (Becton Dickinson, 
San Jose, CA, USA). Data were stored and processed using FACSDiva software (Becton 
Dickinson Immunocytometry System, San Jose, CA, USA). The biparametric scatter 
plots were analyzed with FlowJo software version vX.0.7 (Tree Star, Ashland, OR, USA) 
(Fig. 9).  
               
               Fig. 9: Example of cytofluorimetric scatter for erythroid precursors from WT mice. Left panel: analysis of CD44+ 
               Ter119low Pop I corresponding to pro-erythroblasts. Right panel: analysis of CD44+-Ter119+ Pop II, III, IV,   
               corresponding to basophilic, polychromatic and orthochromatic erythroblasts respectively. 
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Population III and IV corresponding to polychromatic and orthochromatic 
erythroblasts and total erythroblasts (CD44+Ter119+FSChigh) were sorted from bone 
marrow of both mouse strains as previously reported.7 Sorted cells were used for (i) 
morphological analysis of erythroid precursors on cytospin preparations stained with 
May Grunwald-Giemsa; (ii) immunoblot analysis and (iii) RT-PCR analysis.5,6 For 
immunoblot analysis the following specific antibodies were used: anti P-Ser473-Akt, 
anti Akt, anti P-Ser2448-mTOR, anti mTOR (Cell Signaling, Massachusetts, USA), anti P-
Ser40-Nrf2, anti catalase, anti Nrf2, anti Prx1, anti Prx2, anti p62, anti Rab5 (Abcam, 
Cambridge, UK), anti Keap1 (Proteintech, Manchester, UK), anti GATA-1, anti HSP70, 
anti G6PD, anti NQO1 and GAPDH (Santa Cruz Biotechnology, Texas, USA) and HistH3 
(Cell Signaling, Massachusetts, USA) as loading control. Whenever indicated we carried 
out immunoprecipitation (IP) experiments as previously reported.5 Briefly, 1.5*106 
sorted CD44+Ter119+FSChigh cells from WT and Fyn-/- were resuspended in Complete 
Bicine Solution (CBS: Bicine 25 mM, Triton X-100 1.5%, Na3VO4 1 mM, NaF 1 mM, EDTA 
1 mM, in the presence of protease inhibitors) and underwent 3 cycles of freeze/thaw. 
The supernatant was collected and incubated with washed IP beads (Thermo Scientific, 
MA, USA) and phosphoTyr antibodies (PY99; Santa Cruz Biotechnology, Texas, USA and 
4G10; Millipore, Massachussets, USA). The day after beads were spinned down, 
washed with CBS without inhibitors and solubilized with SB2X+β for 1h at RT. Before 
loading gels, beads were heated at 60°C for 4 min.  Filters were incubated overnight 
with anti EPO-R (Sigma-Aldrich, Missouri, USA), anti STAT5, anti Lyn (Santa Cruz 
Biotechnology, Texas, USA), anti Jak2 (Cell Signaling Technology, Danvers, USA) and 
anti IgG rabbit  (GE Healthcare Life Sciences, Little Chalfont, UK) as loading control. 
Secondary anti-rabbit and anti-mouse antibodies were purchased from GE Healthcare 
Life Biosciences (Little Chalfont, UK). Images were acquired using Image Quant Las Mini 
4000 Digital Imaging System (GE Healthcare Life Sciences, Little Chalfont, UK). 
 
          6.5 Annexin V analysis of mouse erythroid precursors 
Analysis of apoptotic erythroblasts from WT and Fyn-/- mice was carried out on the 
CD44-Ter119 gated cells using the Annexin-V PE Apoptosis detection kit (eBioscience, 
San Diego, CA, USA) following the manufacturer instructions8. Flow cytometric analysis 
was carried out with the FACSCantoIITM flow cytometer (Becton Dickinson, San Jose, 
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CA, USA). Data were stored and processed using FACSDiva software (Becton Dickinson 
Immunocytometry System, San Jose, CA, USA). The biparametric scatter plots were 
analyzed with FlowJo software version vX.0.7 (Tree Star, Ashland, OR, USA). 
 
6.6 Analysis of ROS levels on different populations of erythroid precursors 
The ROS levels of erythroid precursors from WT and Fyn-/- mice were determined using 
the General Oxidative Stress Indicator CM-H2DCFDA (LifeTechnologies, Carlsbad, CA, 
USA) on erythroid precursors as previously described9 with minor changes. Briefly, 
CD44-PE, Ter119-APC, CD45-APC-Cy7 (eBioscience, San Diego, USA) stained cells, from 
mouse bone marrow, were incubated with CM-H2DCFDA (10 μM in PBS, BSA 1% at 37°C 
for 20 min). Cells were then washed once with PBS BSA 1%, stained in ice with 7-AAD 
and analyzed with the FACSCantoIITM flow cytometer (Becton Dickinson, San Jose, CA, 
USA). Data were stored and processed using FACSDiva software (Becton Dickinson 
Immunocytometry System, San Jose, CA, USA). The biparametric scatter plots were 
analyzed with FlowJo software version vX.0.7 (Tree Star, Ashland, OR, USA). 
 
6.7 Murine BFU-E and CFU-E assay 
Incomplete MethoCult™ (M3234) media was thawed at room temperature (15 - 25°C) 
or overnight at 4°C. 0.2*106 cells from BM of WT and Fyn-/- mice were collected in 
Complete α-MEM (α-MEM, 1% Penicillin-Streptomicin, 1% Hydrocortisone, 1% 
nucleotides, Gentamicin 0,025 mg/L, Amphotericin 0,5 ug/mL) and then added to 
MethoCult™ media. Growth factors (SCF 50 ng/mL, IL-3 10 ng/mL and EPO  3U/mL) 
were added fresh every time to complete α-MEM. Media were vortexed to ensure all 
components were thoroughly mixed (let the tube stand for at least 5 minutes to allow 
the bubbles to rise to the top). MethoCult™ mixture containing cells was dispensed 
into sterile culture dishes. Empty wells were filled with sterile water. The plates were 
incubated at 37°C and 5% CO2. After 5 and 10 days, WT and Fyn-/- CFU-Es and BFU-Es, 
were picked up, counted and solubilize in CBS with inhibitors. We carried out IP 
experiments on WT and Fyn-/- CFU-Es. Briefly, 2*106 CFU-Es from WT and Fyn-/- were 
resuspended in CBS with inhibitors and underwent 3 cycles of freeze/thaw. The 
supernatant was collected and incubated with washed IP beads and phosphor-Tyr 
antibodies (PY99; Santa Cruz Biotechnology, Texas, USA and 4G10; Millipore, Billerica, 
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Massachusetts, USA). The day after beads were spinned down, washed with CBS 
without inhibitors and solubilized with SB2X+β for 1h at RT. Before loading gels, beads 
were heated at 60°C for 4 min.  Filters were incubated overnight with anti EPO-R 
(Sigma-Aldrich, Missouri, USA), anti STAT5, anti Lyn (Santa Cruz Biotechnology, Texas, 
USA), anti Jak2 (Cell Signaling Technology, Danvers, USA) and anti IgG rabbit (GE 
Healthcare Life Sciences, Little Chalfont, UK) as loading control.  
 
6.8 In vitro maturation of reticulocytes from WT and Fyn-/- mice after PHZ treatment 
WT and Fyn-/- mice were intraperitoneally injected with PHZ (40 mg/kg) at day 0, 1 and 
3. One week after the first injection of PHZ, blood from WT and Fyn-/- mice was 
collected.10 Washed and packed RBCs from heparinized whole blood were used for (i) 
cytosol preparation, as previously described11-13, (ii) LysoTrack and MitoTrack staining 
and (iii) in vitro maturation of reticulocytes. For in vitro maturation, blood was diluted 
1:500 in 1.5 ml of maturation medium (60% IMDM, 2mM L-glutamine, 100U Penicillin-
Streptomicin, 30% FCS, 1% BSA and 1X Amphotericin) and cultured in a 24-well tissue 
culture plate in a cell culture incubator at 37°C with 5% of CO2 for 3 days. 
 
6.9 MitoTracker and LysoTracker analysis on RBCs and cultured reticulocytes after 
PHZ treatment  
RBCs and cultured reticulocytes from PHZ treated WT and Fyn-/- mice underwent 
lysosome and mitochondria staining using the Lysotracker Green DND-26 
(ThermoFisher Scintific) and the MitoTracker Deep Red (ThermoFisher Scientific), 
following the manufacturer’s instructions.14 Cells were analyzed with the 
FACSCantoIITM flow cytometer (Becton Dickinson, San Jose, CA, USA). Data were stored 
and processed using FACSDiva software (Becton Dickinson Immunocytometry System, 
San Jose, CA, USA). The biparametric scatter plots were analyzed with FlowJo software 
version vX.0.7 (Tree Star, Ashland, OR, USA). 
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  7. RESULTS 
7.1 Fyn-/- mice display a mild mycrocitic anemia 
We first analyzed the hematological parameters of wild-type (WT) and Fyn-/- mice 
(Table 3). Fyn-/- mice showed a very mild hypochromic anemia as defined by reduction 
in hemoglobin (Hb) levels and lower mean corpuscular volume (MCV) (Table 3). This 
was associated with slight but significant increase in reticulocyte count in Fyn-/- mice 
compared to WT.  
 
TABLE 3. HEMATOLOGICAL DATA OF WT AND Fyn-/- MICE 
 WT mice 
(n=10) 
Fyn-/- mice 
(n=10) 
Hct (%) 48.2 ± 1.3 46.1 0.8* 
Hb (g/dl) 15.9 ± 0.6 14.3 0.5* 
MCV (fl) 50.3 ± 0.4 46.5 1.3* 
MCH (g/dl) 15.3 ± 0.3 14.8 1.1 
CHCM (g/dL) 26.4±0.5 29.6 ± 1.4* 
RDW (%) 11.6 ± 0.3 13.2 0.4* 
Retics (103 cells/uL) 451± 40.7 559 45* 
 
                Hct: hematocrit; Hb: hemoglobin; MCV: mean corpuscular volume; MCH: mean corpuscular haemoglobin;   
                CHCM: mean cellular hemoglobin concentration; RDW: red blood cell distribution width; Retics: 
                reticulocytes; *p <0.05 compared to WT mice. 
            
           
Increased total bilirubin (TB) and plasma lactate dehydrogenase (LDH) levels were 
observed in Fyn-/- mice compared to healthy controls (Fig. 1a). Up-regulation of 
haptoglobin (Hp) gene expression was found in liver from Fyn-/- mice (Fig. 1b, left 
panel); whereas, plasma Hp levels showed a trend to increase without reaching 
statistical significance compared to WT (Fig. 1b, right panel). No iron-overload was 
detected in either liver or spleen from Fyn-/- mice (Fig. 1c). Up-regulation of EPO mRNA 
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expression was found in Fyn-/- mice (Fig. 1d). Collectively, these data suggest the 
presence of a very mild hemolytic compensated microcytic anemia in mice genetically 
lacking Fyn.  
 
 
 
 
Fig. 1: (a): TB and plasma LDH levels. Data are presented as means±SD (n=6); *p< 0.05 compared to WT mice [in 
collaboration with Prof E.Tolosano, Universityof Torin, Italy]. (b): RT-PCR expression of Hp on liver from WT and Fyn-
/- mice. Experiments were performed in triplicate. Error bars represent the standard deviations (means±SD); *p< 
0.05 compared to WT mice. [in collaboration with Prof. A. Iolascon and Dr. L. De Falco, University Federico II, 
Naples]; Immunoblot analysis of Hp in WT and Fyn-/- mice. Ponceau Red was used as loading control (densitometric 
analysis are reported in supplementary data); Plasma levels of Hp in WT and Fyn-/- mice [in collaboration with Prof 
E.Tolosano, University of Torin, Italy]. (c): Iron staining (Pearl’s Prussian blue) in liver and spleen from WT and Fyn-
/- mice. One representative image from the other six with similar results is presented. (d):  RT-PCR expression of 
EPO on kidney from WT and Fyn-/- mice. Experiments were performed in triplicate. Error bars represent the standard 
deviations (means±SD); *p< 0.05 compared to WT mice [in collaboration with Prof. A. Iolascon and Dr. L. De Falco, 
University Federico II, Naples]. TB, total bilirubin; LDH, lactate dehydrogenase; RT-PCR, real time polymerase chain 
reaction; Hp, haptoglobin; EPO, erythropoietin. 
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          7.2 The absence of Fyn is associated with dyserythropoiesis, increased oxidative       
          stress and low GATA-1 nuclear translocation 
We carried out morphological analysis of sorted erythroblasts from WT and Fyn-/- mice. 
As shown in Fig. 2a, signs of dyserythropoiesis mainly involving Pop II and Pop III were 
detected in Fyn-/- mice compared to WT. This was associated with increased erythroid 
precursors (CD71+Ter119+cells; Fig. 2b) without evidences of extramedullary 
erythropoiesis. We then measured the generation of ROS in sorted erythroblasts from 
both mouse strains. We found higher ROS levels in Fyn-/- erythroblasts compared to 
WT (Fig. 2c, upper panel). Increased amount of Annexin-V positive erythroblasts was 
found in Fyn-/- mice (Fig. 2c; lower panel).  
 
 
Fig. 2: (a): Morphological analysis of cytospins from sorted WT and Fyn-/- erythroblasts stained with May-Grunwald-
Giemsa. Representative micropictures from other six with similar results. (b): Analysis of total erythroblasts in WT 
and Fyn-/- mice (Ter119-CD71 based gating). Data are presented as means±SD (n= 8); *p< 0.05 compared to WT 
mice. (c) Upper panel: ROS levels of erythroblast in populations II - IV from WT and Fyn-/- mice (Pop II, basophilic 
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erythroblasts; Pop III, polychromatic erythroblasts; Pop IV, orthochromatic erythroblasts). Data are presented as 
means±SD (n=8); *p< 0.05 compared to WT mice. Lower panel: Annexin-V+ erythroblasts in populations II-IV from 
WT and Fyn-/- mice (Pop II, basophilic; Pop III, polychromatic; Pop IV, orthochromatic erythroblasts). Data are 
presented as means±SD (n=8); *p< 0.05 compared to WT mice. (d): Immunoblot analysis with specific antibody 
against GATA-1 and HSP70 on cytosolic and nuclear fraction of sorted CD44+Ter119+FSChigh cells. GAPDH and HistH3 
were used as loading controls. One representative gel from three with similar results is presented. Densitometric 
analysis are reported in supplementary data. (e): RT-PCR expression of HBB major, HBB minor and HBA1 on sorted 
Pop III and Pop IV from WT and Fyn-/- bone marrow (Pop III, polychromatic erythroblasts; Pop IV, orthochromatic 
erythroblasts). Experiments were performed in triplicate. Error bars represent the standard deviations (means±SD 
[in collaboration with Prof. A. Iolascon and Dr. L. De Falco, University Federico II, Naples]. (f): TAU Gel 
Electrophoresis of α/β-globins from WT and Fyn-/- circulating red cells. ROS, reactive oxygen species; TAU, Triton-
Acetic-Urea; RT-PCR, real time polymerase chain reaction. 
 
β-thalassemia (β-thal; see also introduction section 3.1) is a human model of stress 
erythropoiesis and it is characterized by increased ROS levels and hyperactivation of 
Jak2-STAT5 signaling pathway. In β-thal erythropoiesis oxidation affects nuclear 
translocation of GATA-1, a key transcriptional factor involved in erythroid maturation 
events. Thus, we evaluated GATA-1 in Fyn-/- erythropoiesis. In sorted Fyn-/- 
erythroblasts, we observed reduced GATA-1 nuclear translocation compared to WT 
(Fig. 2d). This was associated with increased HSP70 nuclear translocation, similarly to 
that described in β-thal erythroblasts. Indeed, a significant decrease in β-globin chain 
synthesis, was evident in Fyn-/- mouse erythroblasts (Fig. 2e). An accumulation of the 
α-globin chains (α-globin aggregates) was detected in circulating Fyn-/- red cells (Fig. 
2f). These data suggest a possible reduced efficiency of EPO signaling cascade in the 
absence of Fyn.  
 
7.3 The absence of Fyn is associated with reduced efficiency of EPO-signaling 
pathway  
We then explored Jak2-STAT5 Tyr-phosphorylation state, which is strictly dependent 
on the efficiency of EPO signaling cascade. In sorted Fyn-/- erythroblasts, we observed 
reduced activation of EPO-R (decreased Tyr-phosphorylation state of EPO-R), 
compared to WT erythroblasts (Fig. 3a). This was associated with increased Jak2 
compensatory activation, without major difference in Lyn functional state (Fig 3a). In 
sorted Fyn-/- erythroblasts, STAT5 activation was significantly decreased, as supported 
by down-regulation of Cish, an exclusively STAT5 regulated gene (Fig. 3b).  
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Using the vitro erythroid cell forming colony unit assay, we found a lower CFU-E and 
BFU-E cells production from Fyn-/- bone marrow cells in presence of standard EPO 
stimulation (3 U/ml) (Fig. 3c). This was again associated with decreased activation of 
EPO mediated signaling cascade in Fyn-/-  CFU-E with compensatory hyperactivation of 
Jak2 (Fig. 3d). Since the absence of Fyn results in low efficiency of EPO signaling 
cascade, the hyperactivation of Jak2 may be related to increase ROS levels 
characterizing Fyn erythroblasts. 
To better understand the role Fyn in EPO-signaling cascade, we treated both mouse 
strains with recombinant EPO (10 U/day for 5 days; red arrows in Fig. 4a).3 Increase of 
Hct and reticulocytes (as CD71+Ter119+ circulating cells) was blunted in Fyn-/- mice 
compared to WT animals (Fig. 4a). Collectively, these data indicate a reduction in the 
efficiency of EPO signaling pathway in the absence of Fyn.  
 
 
 
Fig. 3: (a): Anti phosphor-Tyr immunoprecipitation analysis of Jak2-STAT5 signaling pathway on sorted 
CD44+Ter19+FSChigh cells from WT and Fyn-/- mice. IgG were used as loading control. One representative gel from 
three with similar results is presented. Densitometric analysis are reported in supplementary data. (b): RT-PCR 
expression of Cish on sorted Pop III and Pop IV from WT and Fyn-/- bone marrow (Pop III, polychromatic 
erythroblasts; Pop IV, orthochromatic erythroblasts). Experiments were performed in triplicate. Error bars 
represent the standard deviations (means±SD); *p< 0.05 compared to WT mice. [in collaboration with Prof. A. 
Iolascon and Dr. L. De Falco, University Federico II, Naples]. (c): In vitro colony-forming unit assay of BFU-Es and 
CFU-Es from WT and Fyn-/- mice. Data are presented as means±SD (n=5); *p< 0.05 compared to WT mice. (d): anti 
phosphor-Tyr immunoprecipitation analysis of Jak2-STAT5 signaling pathway on CFU-Es from WT and Fyn-/- mice. 
IgG were used as loading control. One representative gel from three with similar results is presented. Densitometric 
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analysis are reported in supplementary data.  RT-PCR, real time polymerase chain reaction; CFU-E, erythroid colony-
forming unit; BFU-E, erythroid burst-forming unit. 
 
7.4 Fyn-/- mice display a high sensitivity to PHZ or Doxorubicin induced stress 
erythropoiesis 
We then treated both mouse strains with either PHZ (40 mg/Kg; red arrows in Fig. 4b) 
or Doxorubicin (0.25 mg/Kg; red arrow in Fig. 5a). In mice, PHZ is known to induce 
severe oxidation and acute hemolytic anemia, while Doxorubicin temporary represses 
erythropoiesis with ROS generation.1,2 
As shown in Fig. 4b, PHZ induced a similar marked drop in Hct levels in both mouse 
strains at day 2 after PHZ injection. In Fyn-/- mice, we observed a delayed increase in 
Hct levels at day 4 and 8 compared to WT. The increase in reticulocyte count in PHZ 
treated Fyn-/- mice was blunted compared to WT mice, showing a peak at day 8 after 
PHZ injection (Fig. 4b). As shown in Fig. 4c, we found increased levels of total 
erythroblasts in bone marrow and spleen from both mouse strains following PHZ 
injection. In Fyn-/- spleen, the increase in erythroid precursors was blunted at day 4, 
with a compensatory increase at day 14 after PHZ administration (Fig. 4c, upper panel). 
In bone marrow, we observed a mild increase in total erythroblasts in both mouse 
strains at day 2 and 4 after PHZ injection (Fig. 4c, lower panel). Noteworthy, in Fyn-/- 
mice we found a marked increase in bone marrow total erythroblasts at day 8 after 
PHZ, suggesting a possible compensatory mechanism in Fyn-/- mice do to the lack of 
splenic response following PHZ treatment (Fig. 4c, lower panel). At day 4 and 8 after 
PHZ injection, the amount of Annexin-V+ cells was higher in Fyn-/- polychromatic and 
orthochromatic erythroblasts in both bone marrow and spleen compared to WT 
animals (data not shown).  
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Fig. 4: (a): Hematocrit (Hct) and reticulocyte count in WT and Fyn-/- mice after EPO injection (10 U/mice; red arrows). 
Data are presented as means±SD (n= 5).  (b): Hematocrit (Hct) and reticulocyte count in WT and Fyn-/- mice after 
PHZ injection (40 mg/kg, red arrow). Data are presented as means±SD (n= 5); *p< 0.05 compared to WT mice (c): 
Total erythroblasts in WT and Fyn-/- bone marrow and spleen after PHZ injection. Data are presented as means±SD 
(n= 5); *p< 0.05 compared to WT mice. EPO, erythropoietin; PHZ, phenylhydrazine; Hct, hematocrit. 
 
In Fyn-/- mice, Doxorubicin induced a more severe and prolonged anemia compared to 
WT. We also found a delay in reticulocytes response compared to Doxorubicin treated 
WT animals (Fig. 5a). Total erythroblasts were determined at day 9 after Doxorubicin 
administration in both spleen and bone marrow.2 In Fyn-/- mice, we observed a 
significant reduction in both bone marrow and spleen erythroblasts, compared to 
vehicle treated controls (Fig. 5b). Increased amount of Annexin V+ polychromatic and 
orthochromatic erythroblasts was observed at day 9 after Doxorubicin administration 
in Fyn-/- mice compared doxorubicin treated WT animals (data not shown).  
These data suggest an increased sensitivity of Fyn-/- mice to stress erythropoiesis, 
further supporting the importance of Fyn in EPO signaling cascade. 
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Fig. 5: (a): Hematocrit (Hct) and reticulocyte count in WT and Fyn-/- mice after Doxorubicin injection (0.25 mg/kg; 
red arrow). Data are presented as means±SD (n= 5); *p< 0.05 compared to WT mice. (b): Analysis of total 
erythroblasts in bone marrow and spleen from WT and Fyn-/- mice after Doxorubicin injection. Data are presented 
as means±SD (n= 5). *p< 0.05 compared to WT mice. DOXO, doxorubicin; Hct, hematocrit. 
 
 
7.5 Fyn-/- mice display increased Akt 
Previous studies have shown that EPO-Jak2 pathway can activate Akt, which is also 
directly modulated by ROS (Fig. 6a).15 Thus, we evaluated Akt function in sorted 
erythroblasts from both mouse strains. As shown in Fig. 6b, Fyn-/- mouse erythroblasts 
displayed increased active Akt (Ser 473) compared to WT cells (Fig. 6b). Activation of 
Akt might affect multiple targets involved in response to oxidation. Akt might (I) 
functionally interact with the redox sensitive transcriptional factor Nrf2, resulting in 
Nrf2 activation; or (II) activate mTOR, which phosphorylation represses autophagy.15,16 
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Fig. 6: (a): Schematic representation of EPO signaling pathway intercrossed with autophagy and Nrf2 redox-
sensitive systems. (b):  Immunoblot analysis with specific antibodies against p-Ser473-Akt and Akt from WT and Fyn-
/- sorted CD44+Ter119+FSChigh erythroblasts. GAPDH was used as loading control. One representative gel from three 
with similar results is presented. Densitometric analysis are reported in supplementary data. (c): Immunoblot 
analysis with specific antibodies against p-Ser40-Nrf2 and Nrf2 from WT and Fyn-/- sorted Pop III and Pop IV (Pop III, 
polychromatic erythroblasts; Pop IV, orthochromatic erythroblasts). GAPDH was used as loading control. One 
representative gel from three with similar results is presented. Densitometric analysis are reported in 
supplementary data. (d): RT-PCR expression of Catalase, G6pd, Gpx1, Hmox1 and Prx2 on sorted Pop III and Pop IV 
from WT and Fyn-/- bone marrow (Pop III, polychromatic erythroblasts; Pop IV, orthochromatic erythroblasts). 
Experiments were performed in triplicate. Error bars represent the standard deviations (means±SD); *p< 0.05 
compared to WT mice. [in collaboration with Prof. A. Iolascon and Dr. L. De Falco, University Federico II, Naples].  
 
In Fyn-/- erythroblasts, we found increased activation of Nrf2 (Ser40) compared to WT 
cells, most likely related to the absence of Fyn as key post-induction regulator of Nrf2 
(Fig. 6c). This was supported by up-regulation of ARE-genes for anti-oxidant and 
cytoprotective systems such as Catalase, G6PD, GPX1, HO-1 and Prx2 (Fig. 6d). 
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Immunoblot analysis with specific antibodies showed increased expression of the 
encoded proteins, validating the molecular data (Fig. 7). 
 
 
Fig. 7:  Immunoblot analysis with specific antibodies against G6PD, HO-1, Prx2, Prx1 and NQO1 from WT and Fyn-/- 
sorted Pop III and Pop IV. GAPDH was used as loading control. One representative gel from three with similar results 
is presented. Densitometric analysis are reported in supplementary data. 
 
7.6 In Fyn-/-mice, activation of mTOR impairs autophagy, leading to abnormalities on 
the in vitro reticulocyte maturation 
Previous studies have shown that autophagy plays a key role in erythropoiesis, 
contributing to the correct maturation and differentiation of erythroid precursors (ref). 
Although modulation of mTOR during erythropoiesis is only partially known, mTOR is 
a key protein in autophagy and its activation by Akt represses autophagy.16 In Fyn-/- 
mouse erythroblasts, we found increased active mTOR (Ser2448) associated with 
accumulation of p62 and Rab5, both proteins involved in late phase of autophagy (Fig. 
8a). Moreover, in Fyn-/- erythroblasts, we found accumulation of Keap1, the physiologic 
inhibitor of Nrf2 (Fig. 8a).17 These data suggest an impairment of autophagy processes 
during erythropoiesis in the absence of Fyn. 
Since autophagy has been shown to be important during reticulocyte maturation18, we 
analyzed in vitro reticulocyte maturation from PHZ treated mice.10 We found reduced 
Fyn-/- reticulocyte maturation compared to WT (Fig. 8b, left panel). This was associated 
with decreased lysosomal clearance, as shown by LysoTrack analysis, without major 
difference in mitochondrial clearance, as shown by MitoTrack analysis (Fig. 8b, right 
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panel). An accumulation of p62, was again detected in maturing reticulocytes in the 
absence of Fyn, further supporting the impairment of autophagy in Fyn-/- mice (Fig. 8c).  
 
 
Fig. 8: (a):  Immunoblot analysis with specific antibodies against p-Ser2448-mTOR, mTOR, p62, Keap1 and Rab5 
from WT and Fyn-/- sorted CD44+Ter119+FSChigh erythroblasts. GAPDH was used as loading control. One 
representative gel from three with similar results is presented. Densitometric analysis are reported in 
supplementary data.  (b) (Left) Flow cytometric scatter of RBCs at day 0 and after 3 days of in vitro maturation from 
PHZ treated WT and Fyn-/- mice. One representative of 3 independent experiments with similar results. Data are 
shown as means±SD (n=3); *p< 0.05 compared to WT mice. (Right) Flow cytometry of RBCs at day 0 and after 3 
days of in vitro maturation from PHZ treated WT and Fyn-/- mice intravitally stained with LysoTracker and 
MitoTracker. One representative of 3 independent experiments with similar results. Data are shown as means±SD 
(n=3); *p< 0.05 compared to WT mice. (c): Immunoblot analysis with specific antibodies against p62 in RBCs at day 
0 and after 3 days of in vitro maturation from PHZ treated WT and Fyn-/- mice. Catalase was used as loading control.  
One representative gel from three with similar results is presented. Densitometric analysis are reported in 
supplementary data. 
 
 
 
   
7.7 The mTOR inhibitor Rapamycin unlocks autophagy and ameliorates 
erythropoiesis in Fyn-/- mice  
We then treated both mouse strains with Rapamycin (10 mg/Kg), a known mTOR 
inhibitor, which has been shown to promote autophagy and beneficially impact stress 
erythropoiesis in other mouse models.4 
Rapamycin administration reduced total bone marrow Fyn-/-mouse erythroblasts, 
while no significant effects were observed in control animals as previously reported 
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(Fig. 9a).4 A significant reduction in generation of ROS and in the amount of Annexin- 
V+ cells was found only in erythroid precursors from Fyn-/- mice (Fig. 9b, 9c). In 
agreement with the activation of autophagy we observed decreased levels of p62 in 
Rapamycin treated Fyn-/- erythroblasts compared to vehicle treated animals (Fig. 9d). 
No major change was observed in hematologic parameters as previously reported.4  
These data suggest that the inhibition of mTOR unlocks autophagy and ameliorates 
erythropoiesis in Fyn-/- mice.   
 
 
 
 
Fig. 9: (a): Analysis of total erythroblasts in WT and Fyn-/- bone marrow (Ter119-CD44 based gating) treated with 
either vehicle or Rapamycin. Data are presented as means±SD (n= 5); *p< 0.05 compared to WT mice; °p < 0.05 
compared to vehicle treated mice (b): ROS levels of erythroblast in populations II - IV from WT and Fyn-/- mice 
treated with either vehicle or Rapamycin (Pop II, basophilic erythroblasts; Pop III, polychromatic erythroblasts; Pop 
IV, orthochromatic erythroblasts). Data are presented as means±SD (n=5); *p< 0.05 compared to WT mice; °p < 0.05 
compared to vehicle treated mice. (c): Annexin-V+ erythroblasts in populations II-IV from WT and Fyn-/- mice treated 
with either vehicle or Rapamycin. (Pop II, basophilic; Pop III, polychromatic; Pop IV, orthochromatic erythroblasts). 
Data are presented as means±SD (n=5); *p< 0.05 compared to WT mice; °p < 0.05 compared to vehicle treated mice. 
(d): Immunoblot analysis with a specific antibody against p62 from Fyn-/- sorted CD44+Ter119+FSChigh erythroblasts 
treated with either vehicle or Rapamycin. Catalase was used as loading control. One representative gel from three 
with similar results is presented. Densitometric analysis are reported in supplementary data. 
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8. DISCUSSION 
Here, we found a novel role of Fyn in EPO-mediated signaling pathway in normal and 
stress erythropoiesis. Fyn affects EPO-R and STAT5 Tyr-phosphorylation state, without 
change in Lyn activity but overactivation in Jak2 (Fig. 3). This suggests Fyn as a new 
downstream regulator of STAT5 phosphorylation similarly to that described in Lyn-/- 
mice.3 We carried out a protein alignment using ClustalW2 for Fyn and Lyn (Fig. 10). 
The superposed alignment gives a 62% identity and 78% sequence similarities using 
Blastp algorithm (Fig. 10).  
 
Alignment Score: 54.30 
                                                     Fig. 10: ClustalW2 alignment between Fyn and Lyn kinases  
 
 
Previous studies have shown that Lyn targets STAT5, modulating its Tyr-
phosphorylation state.3 The high similarity between Fyn and Lyn allow us to propose 
Fyn as possible new modulator of STAT5 in erythroid cells.   
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The reduction in STAT5 activation observed in Fyn-/- mouse erythroblasts supports this 
interplay and it is in agreement with previous reports in other cell types (i.e. such mast 
cells and CML cells)19,20. In Fyn-/- mice, the reduction in STAT5 activation may be 
responsible for the microcytic anemia as previously reported in mice genetically lacking 
STAT5.21 
In Fyn-/- mice, the reduced efficiency of EPO signaling pathway was also indicated by 
increased ROS levels and cell apoptosis of the different erythroblast subpopulations 
(Fig. 2). The synergic effect of reduced EPO signaling and increased oxidation results in 
decreased GATA-1 nuclear translocation similarly to that observed in β-thal 
erythropoiesis.22 Indeed, the unbalance in β-globin chain synthesis with accumulation 
of free α-globin chains further support the functional impact of Fyn on erythroid 
maturation (Fig. 2). 
We then explored Jak2/STAT5 pathway in early and late erythropoiesis in Fyn-/- mice. 
The reduction in STAT5 activity observed in both erythroblasts and erythroid 
progenitors (CFU-Es) indicate the critical role of Fyn in modulating the temporary 
dynamics of EPO-induced erythroid maturation (Fig. 3). In Fyn-/- mice, failure in 
response to recombinant EPO supports the proposed role for Fyn in EPO signaling 
cascade (Fig 4a).  
To understand the role of Fyn in stress erythropoiesis, we exposed Fyn-/- mice to either 
PHZ or Doxorubicin. Fyn-/- mice display high sensitivity to both PHZ and Doxorubicin 
with a blunt response of erythropoiesis to these stressful conditions (Fig. 4b, 5). In Fyn-
/- mice, increased oxidation results in Jak2 overoxidation leading to increased activity 
of Akt that is an important signal to ensure erythroid survival and maturation (Fig 
6b).23,24 Akt intersects several pathways such as Nrf2, a redox sensitive transcriptional 
factor, and mTOR, the gatekeeper of autophagy.15,16 Fyn-/- mice display activation of 
Nrf2, resulting in up-regulation of ARE genes and the related encoded proteins for 
antioxidant systems (Fig. 6, 7). However, the up-regulation of these cytoprotectors is 
unable to counteract oxidation of Fyn-/- erythroblasts. In cell homeostasis, the 
prolonged oxidation might overcome autophagy, resulting in cell apoptosis.25 This 
seems to be the case of Fyn-/- erythroblasts where we found increased cell apoptosis 
(Fig. 2c). It is of note that Fyn-/- mouse erythroblasts display mTOR activation resulting 
in impairment of autophagy as supported by accumulation of p62. Since p62 is an 
54 
 
autophagy adaptor important in protein quality control system, the accumulation of 
p62 is generally used as a marker of blockage of the autophagic flux.25,26 Thus, we 
propose that the absence of Fyn might result in impairment of late phase of autophagy 
during erythroid maturation (Fig. 8a). In agreement, we found a reduction in in vitro 
reticulocyte maturation with delayed lysosomal clearance and again accumulation of 
p62 in Fyn-/- mouse reticulocytes (Fig. 6b, c). Our group has recently reported an 
impairment of autophagy with accumulation of p62 in both erythroblasts and red cells 
from patient with chorea acanthocytosis. This, further support the crucial role of 
autophagy in erythropoiesis.27 Since no change in mitochondrial clearance was found 
in Fyn-/- in vitro maturating reticulocytes, we might reasonably exclude alteration of 
mitophagy in Fyn-/- mice. This is also supported by similar Nix protein content observed 
in in vitro maturating reticulocytes from both mouse strains (data not shown).25,27 
We carried out the revision of the literature on pharmacologic activators of autophagy 
and erythropoiesis. (Table 4). 
 
 
Table 4. Studies on the effects of Rapamycin on erythropoiesis and diseased red cells 
 Main results Ref. 
Rapamycin  
(10 mg/kg) in 
C57B6/2J mice 
for 3 days 
-Relative low impact on erythroid growth and proliferation: 
reduction in the reticulocyte count, without changes in 
reticulocyte volume or Hb content per cell; 
-No significant effect on bone marrow adult erythropoiesis: 
slight reduction of early erythroid precursors without major 
differences; 
-No significant alterations on mTORC1 downstream signaling 
pathway in reticulocytes: weak reduction in S6 kinase (S6K) 
activity, a widely used marker for mTOR activation; 
-Co-administration of PHZ (50 mg/kg) and Rapamycin delays 
the response to stress erythropoiesis: 
• Increased mortality of mice after 6 days following PHZ; 
• Delayed release of stress reticulocytes and decrease in 
spleen size compared to PHZ-treated mice; 
• Reduced early erythroid precursors proliferation in the 
spleen, suggesting a critical role of mTORC1 signaling 
during stress erythropoiesis;  
• No major changes in EPO levels. 
 
[4] 
MLN0128,  
a selective mTOR 
inhibitor  
-Profound effects on erythroid growth and proliferation:  
• decrease in reticulocytes number, volume and 
hemoglobin content; 
[4] 
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(2 mg/kg) in 
C57B6/2J mice 
for 3 days 
• Decreased proliferation of early erythroid precursors 
with increased late stage erythroblasts; 
• Complete block of mTOR downstream signaling 
pathway; 
-Co-administration of PHZ (50 mg/kg) is lethal after 3 days of 
treatment: critical role of mTORC 1/2 signaling in response to 
acute hemolytic anemia. 
 INK128,  
dual mTORC1/2 
inhibitor 
(1 mg/kg) in 
humanized sickle 
cell mice for 3 
weeks 
-In SCD mice: 
Increased erythrocytes count, Hct and Hb content; 
        Reduced reticulocytosis; 
        Markedly decreased spleen size without changes in total    
        body weight. 
 
[28] 
Sirolimus, 
selective 
mTORC1 inhibitor 
(5 mg/kg) in 
humanized sickle 
cell mice for 3 
weeks 
-In both transplanted and non-transplanted SCD mice,  
• Increased Hct and Hb, after 1 week of treatment; 
• Decreased splenomegaly; 
• Increased RBC lifespan; 
• Improved erythroid maturation; 
• Decreased iron deposition in kidney and liver; 
• Decreased stroke volume (reduced sickling/ vaso-
occlusive crisis). 
[28] 
Rapamycin,  
an mTOR 
inhibitor 
 (4 mg/kg) in 
FOXO3-/-mice for 
5 days/week for 2 
weeks 
- In FOXO3-/-mice and β-thal mice: 
• Increased Hb levels (Foxo3-/- mice and β-thal mice); 
• No major effect on total erythroblast count, but 
ameliorated terminal erythroid differentiation (β-thal 
mice);  
• Blocked cell cycle progression in immature 
erythroblasts (β-thal mice);  
• Amelioration of the β-globin gene expression (β-thal 
mice); 
• Significant reduction in EPO levels; 
[29] 
EPO: erythropoietin; mTOR: mammalian target of Rapamycin; PHZ: phenylhydrazine; Hct: hematocrit; Hb: 
hemoglobin; β-thal: β-thalassemia; SCD: sickle cell disease; RBC: red blood cell 
 
 
These results suggest that autophagy plays a key role in erythroid maturation and that 
modulation of the autophagic process might beneficially impact diseased 
erythropoiesis.4,28,29 In our model, Rapamycin administration reduces total 
erythroblasts and ameliorates cellular homeostasis by reduction of oxidation (Fig. 9a, 
b). The activation of autophagy reduces cell apoptosis as indicated by the decrease 
amount of Annexin V+ cells (Fig. 9c). The restoration of the balance between apoptosis 
and autophagy results in decreased cellular levels of p62 (Fig. 9d). Our data indicate 
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that the absence of Fyn might affect autophagic lysosomal clearance system, which is 
particularly crucial during reticulocyte maturation.  
In conclusion, we unveil the role of Fyn as a new kinase in EPO signaling cascade, 
increasing the complexity of EPO pathway, which already requires Jak2 as primary 
kinase and Lyn as additional kinase.30 In Fyn-/- mice, the overactivation of Jak2 increases 
Akt function, resulting in persistent activation of Nrf2 and impairment of autophagy by 
mTOR activation. This results in cellular dysfunction which becomes evident when Fyn-
/- mice were exposed to stressful conditions, such as PHZ or Doxorubicin. 
 
Future studies will be designed to further characterize the signaling pathways 
intersects by Fyn in normal and diseased erythropoiesis. The co-administration of 
Rapamycin with PHZ, will help us in dissecting the contribution of activated autophagy 
in response to stress erythropoiesis. In Fyn-/- mice, other more selective inhibitors of 
either mTORC1 or mTORC1/2 might be tested to better understand whether the 
beneficial effect of Rapamycin is strictly dependent on its inhibitory effect on mTORC1 
or involves other important factors in autophagy.  
Since intense or persistent oxidation might block autophagy31, we plan to treat Fyn-/- 
mice with N-Acetyl-Cysteine (NAC) as exogenous antioxidant molecule.32,33 
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A B S T R A C T
Pulmonary-artery-hypertension (PAH) is a life-threatening and highly invalidating chronic disorder. Chronic
oxidation contributes to lung damage and disease progression. Peroxiredoxin-2 (Prx2) is a typical 2-cysteine
(Cys) peroxiredoxin but its role on lung homeostasis is yet to be fully deﬁned. Here, we showed that Prx2-/- mice
displayed chronic lung inﬂammatory disease associated with (i) abnormal pulmonary vascular dysfunction; and
(ii) increased markers of extracellular-matrix remodeling. Hypoxia was used to induce PAH. We focused on the
early phase PAH to dissect the role of Prx2 in generation of PAH. Hypoxic Prx2-/-mice showed (i) ampliﬁed
inﬂammatory response combined with cytokine storm; (ii) vascular activation and dysfunction; (iii) increased
PDGF-B lung levels, as marker of extracellular-matrix deposition and remodeling; and (iv) ER stress with acti-
vation of UPR system and autophagy. Rescue experiments with in vivo the administration of fused-recombinant-
PEP-Prx2 show a reduction in pulmonary inﬂammatory vasculopathy and in ER stress with down-regulation of
autophagy. Thus, we propose Prx2 plays a pivotal role in the early stage of PAH as multimodal cytoprotector,
targeting oxidation, inﬂammatory vasculopathy and ER stress with inhibition of autophagy. Collectively, our
data indicate that Prx2 is able to interrupt the hypoxia induced vicious cycle involving oxidation-inﬂammation-
autophagy in the pathogenesis of PAH.
1. Introduction
Pulmonary artery hypertension (PAH) is a life threatening highly
invalidating chronic disorder [1–3]. Although in the last decade
progresses have been made in the identiﬁcations of factors involved in
its pathogenesis, much still remains to be investigated in the me-
chanism involved in the early stage of PAH [3–5]. Regardless of the
initial event, the combination of chronic inﬂammation and chronic
http://dx.doi.org/10.1016/j.freeradbiomed.2017.08.004
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hypoxia promote a high pro-oxidant environment, mediating disease
progression [1,2,4,6,7].
In this scenario, eﬃcient catabolic pathways to either buildup
misfolded/unfolded proteins or to clear intracellular damaged proteins
are required [8–11]. Studies in diﬀerent models of PAH have shown
that cellular response to face the accumulation of damaged proteins is
mainly through endoplasmic reticulum (ER) stress followed by the ac-
tivation of autophagy to clear damaged proteins and to reduce ER stress
[10,12,13]. Indeed, classic chaperones such as heat shock protein 90
and 70 (HSP) are upregulated in PAH, indicating the requirement of
chaperone systems to deal with the accumulation of damaged proteins
[14].
Prx2 is a typical 2-cysteine (Cys) peroxiredoxin ubiquitously ex-
pressed. Prx2 has been largely investigated in erythroid cells, where it is
able to scavenge low concentration of H2O2 without inactivation due to
over-oxidation [15]. Recently, in diﬀerent cell models, Prx2 has been
also linked to chaperone activity, priming cells to better tolerate oxi-
dation [16,17]. Studies in mouse genetically lacking Prx2 (Prx2-/-) have
highlighted its protective role against LPS induced lethal shock and
acute distress syndrome (ARDS), suggesting a possible contribution of
Prx2 in inﬂammatory response [17–23]. In addition, in vitro and in vivo
model of ischemic/reperfusion stress highlighted the key role of Prx2 as
anti-oxidant system [24,25].
Here, we studied the role of Prx2 in development of pulmonary
hypertension in mice genetically lacking Prx2 (Prx2-/-), using hypoxic
stress to explore the early stage of early phase of pulmonary hy-
pertension. Our data collectively indicate that Prx2 plays a pivotal role
in the early phase of hypoxia induced pulmonary hypertension as anti-
oxidant system and chaperone. The administration of Prx2 fused to cell-
penetrating carrier PEP (cell penetrating peptide; PEP Prx2; [19]) (i)
reduces local and systemic inﬂammation; (ii) prevents vascular acti-
vation and PDGF-B up-regulation; (iii) alleviates ER stress and (i) down-
regulates autophagy activation in response to hypoxia. Thus, PEP Prx2
might represent an interesting new multimodal therapeutic option in
the early stage PAH.
2. Materials and methods
2.1. Drugs and chemicals
Details are reported in Supplemental materials and methods.
2.2. Mouse strains and design of the study
C57B6/2J mice as wildtype controls (WT) and Prx2-/- mice aged
between 4 and 6 months both male and female were used in the present
study [19,26]. The Institutional Animal Experimental Committee,
University of Verona (CIRSAL) and by the Italian Ministry of Health
approved the experimental protocols. Where indicated WT and Prx2-/-
mice were treated with 1) N-Acetyl-Cysteine (NAC) at the dosage of
100 mg/kg/d (in NaCl 0.9%, NaOH 36 mM, pH 9.4; ip) or vehicle only
for 3 weeks [19,20]; 2) PEP Prx2 (in PBS) or vehicle at the dosage of
3 mg/kg/d ip or vehicle for 4 weeks before and during hypoxia [19].
Whenever indicated, mice were exposed to hypoxia (8% oxygen for
10 h, 3 days, 7 days) (Hy) as previously described [27–29]. To collect
organs, animals were ﬁrst anesthetized with isoﬂurane, bronch-
oalveolar lavage (BAL) was collected and then mice were euthanized.
Organs were immediately removed and divided into two and either
immediately frozen in liquid nitrogen or ﬁxed in 10% formalin and
embedded in paraﬃn for histology.
2.2.1. Bronchoalveolar lavage (BAL) measurements
BAL ﬂuids were collected and cellular contents were recovered by
centrifugation and counted by microcytometry as previously reported
[27]. Percentage of neutrophils was determined on cytospin cen-
trifugation. Remaining BAL samples were centrifuged at 1500×g for
10 min at 4 °C. The supernatant ﬂuids were used for determination of
total protein content [27].
2.3. Lung molecular analysis
2.3.1. Lung histology
Multiple (at least ﬁve) three-micron whole mount sections were
obtained for each paraﬃn-embedded lung and stained with hematox-
ylin eosin, Masson's trichome, and May-Grünwald-Giemsa. α-smooth
muscle actin immunohistochemistry (IHC) on lungs was carried out as
previously reported [27,30]. Lung pathological analysis was carried out
by blinded pathologists as previously described [27,30]. Based on
previous reports (18, 38), the pathological criteria for lung histo-
pathology were as follows: i) Bronchus: Mucus: 0: no mucus; +: mucus
ﬁlling less than 50% of the area of the bronchus section; ++: mucus
ﬁlling more than 50% of the area of the bronchus section. (ii) In-
ﬂammatory inﬁltrate density: 0: less than 5 inﬂammatory cells per ﬁeld;
+: 5–30 inﬂammatory cells per ﬁeld; ++ more than 30 inﬂammatory
cells per ﬁeld. (iii) Thrombi: 0: no thrombus; + presence of a thrombus
in one ﬁeld, at magniﬁcation 250.
2.3.2. Immunoblot analysis
Frozen lung and heart from each studied group were homogenized
and lysed with iced lyses buﬀer (LB containing: 150 mM NaCl, 25 mM
bicine, 0.1% SDS, Triton 2%, EDTA 1 mM, protease inhibitor cocktail
tablets (Roche), 1 mM Na3VO4 ﬁnal concentration) then centrifuged
10 min at 4 °C at 12,000g. Proteins were quantiﬁed and analyzed by
mono-dimensional SDS polyacrylamide gel electrophoresis. Gels were
transferred to nitrocellulose membranes for immuno-blot analysis with
speciﬁc antibody. Details are reported in Supplemental materials and
methods [21,27,31–33]. Whenever indicated Prx2 dimerization was
studied in lung from PBS perfused mice containing 100 mM NEM, using
an approach similar to that reported by Kumar et al. [34].
2.3.3. RNA isolation, cDNA preparation and quantitative RT-PCR
Total RNA was extracted from tissues using Trizol reagent (Life
Technologies, Monza, Italy). Synthesis of cDNA from total RNA (1 μg)
was performed using Super Script II First Strand kits (Life
Technologies). Quantitative RT-PCR (qRT- PCR) was performed using
the SYBR-green method, following standard protocols with an Applied
Biosystems ABI PRISM 7900HT Sequence Detection system. Relative
gene expression was calculated using the 2(-ΔCt) method, where ΔCt
indicates the diﬀerences in the mean Ct between selected genes and the
internal control (GAPDH). qRT-PCR primers for each gene were de-
signed with Primer Express 2.0 (Life Technologies) (primer sequences
are reported in Table 1S) [27,30].
2.4. MDA assay
MDA was determined as previously reported [35].
2.5. Evaluation of right ventricular hypertrophy and echocardiography
measurements
Hearts were ﬁxed with 10% formaldehyde for 24 h. The right ven-
tricular (RV) free wall was separated from the left ventricular with
septum (LV+S) under dissection microscope. RV and LV + S were
separately weighed and used to calculate the ratios RV/(LV + S)/body
weight [36]. Transthoracic echocardiography was performed with a
Vevo 2100 echocardiograph (Visual Sonics, Toronto, Canada) equipped
with a 22–55 MHz transducer (MicroScan Transducers, MS500D) as
previously reported [27,37].
2.6. Statistical analysis
Data were analyzed using either t-test or the 2-way analysis of
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variance (ANOVA) for repeated measures between the mice of various
genotypes. A diﬀerence with a P value less than 0.05 was considered
signiﬁcant.
3. Results
3.1. Mice genetically lacking Prx2 show lung inﬂammation, increased
pulmonary vascular activation and extracellular-matrix remodeling
Lung histopathologic analysis showed increased peribronchial
edema without changes in the number of mucus cells in Prx2-/- mice
under normoxia compared to wildtype animals (Fig. 1A, upper panel).
The systematic study for α-smooth cells expression showed a staining in
broken line only on bronchial sections of Prx2-/- mice, suggesting an
initial pulmonary vessel muscularization (Fig. 1A, lower panel). In-
creased bronchoalveolar lavage (BAL) levels of proteins and of total
leukocytes were detected in Prx2-/- mice compared to wildtype, in-
dicating an abnormal pulmonary vascular leakage (Fig. 1SA).
In Prx2-/- mice, we observed increased active form of NF-kB and
Nrf2, two redox related transcriptional factors, compared to wildtype
animal (Fig. 1B).
This was associated with increased lung MDA levels (Fig. 1SB) and
up-regulation of the pro-inﬂammatory cytokines IL-6, IL-1b and IL10
that are known targets of NF-kB (Fig. 1C). We conﬁrmed the increased
expression of IL-6 by immunoblot analysis in lung from Prx2-/- mice
compared to wildtype animals (Fig. 1D). The activation of Nrf2 in the
absence of Prx2 was supported by the up-regulation of Nrf2 related
systems such as HO-1, a vascular and lung cytoprotector, and SOD-1, a
potent anti-oxidant enzyme supports (Fig. 1D) [38]. We also observed
higher levels of (i) endothelin-1 (ET-1), the most potent vasoconstric-
tive and broncho-constrictive cytokine [30]; (ii) VCAM-1, a marker of
vascular endothelial activation [27]; and (iii) PDGF-B, a known factor
involved in lung extra-cellular matrix remodeling [39] (Fig. 1D).
These data link the absence of Prx2 with persistent lung in-
ﬂammation, endothelial vascular activation, and extracellular matrix
remodeling.
Fig. 1. The absence of Prx2 promotes lung inﬂammation, increased pulmonary vascular activation and extra-matrix remodeling markers. A. Comparison of Prx2-/- with WT
mice shows an increased peribronchial edema in Prx2-/- mice (upper panel Hematoxylin Eosin ×250) and deposits of alpha actin in vascular walls in Prx2-/- mice (lower panel
Immunohistochemistry using anti alpha actin antibody × 600). B. Immunoblot analysis with speciﬁc antibodies against phospho-NF-kB (P-NF-kB), NF-kB, phospho-Nrf2 (P-Nrf2) and
Nrf2 of lung from wildtype (WT) and Prx2-/- mice under normoxic condition. One representative gel from six with similar results is presented. Right panel. Densitometric analysis (DU:
Density Units) of immunoblots is shown as means± SD (n= 6); *p<0.05 compared to wildtype. C. IL-6, IL-1b, IL-10 mRNA levels in lung tissues (normalized to GADPH) from WT and
Prx2-/- mice. * p< 0.05 (WT vs Prx2-/-). Each sample (WT; Prx2-/-) is a pool from 5 mice. Representative of three independent experiments. D. Immunoblot analysis with speciﬁc
antibodies against IL-6, heme-oxygenase 1 (HO-1), endothelin-1 (ET-1), superoxide dismutase (SOD-1), vascular cell adhesion molecule-1 (VCAM-1), platelet derived growth factor-B
(PDGF-B) and peroxiredoxin-2 (Prx2) of lung from wildtype (WT) and Prx2-/- mice under normoxic condition. One representative gel from six with similar results is presented. Right
panel. Relative quantiﬁcation of immunoreactivity (DU: Density Units) of IL-6, HO-1, SOD1, ET-1, VCAM1, PDGF-B and Prx2 of lung from wildtype (WT) and Prx2-/- mice under
normoxic condition. Data are shown as means± SD (n = 6); *p< 0.05 compared to wildtype.
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3.2. Prolonged hypoxia promotes the development of early stage pulmonary
hypertension in Prx2-/- mice
Based on our previous report, showing the development of early
stage PAH in a mouse model for sickle cell disease but not in wildtype
mice [36], we exposed both mouse strains to hypoxia (Hy) 8% oxygen
for 7 days. As shown in Fig. 2A, hypoxia induced sparse inﬂammatory
cell inﬁltrate with some peribronchial edema in Prx2-/- mice. On the
bronchial epithelium there was no signiﬁcant change in the number of
mucus cells in both mouse strains. On vascular sections, no thrombus
was found in any of the mouse groups. The systematic study for α-actin
deposition revealed the presence of almost linear staining around
bronchial and vascular sections in Prx2-/- mice (Fig. 2A, lower panel).
While, α-actin depositions were sparse in hypoxic wildtype mice.
We evaluated the presence of RV hypertrophy in both mouse strains
exposed to 7days hypoxia. In Prx2-/- mice, we observed a slight but
signiﬁcant increase in RV/(LV + S) ratio (normoxia: 0.21±0.03 vs
hypoxia 0.34±0.05; n = 6, P<0.05), whereas no changes were ob-
served in wildtype mice in agreement with our previous report [36].
This was associated with a signiﬁcant increase in mitral valve decel-
eration time and a reduction in pulmonary acceleration time/ ejection
time ratio (Fig. 2B), indicating early diastolic dysfunction and increased
right ventricular systolic pressure in Prx2-/- mice. In addition, we found
hypoxia induced increased expression of SOD-1 in heart from both
mouse strains, but to a higher extent in Prx2-/- mice (Fig. 1SD). Hypoxia
induced up-regulation of (i) VCAM-1 and ICAM-1; and (ii) atrial na-
triuretic peptide (ANP) was also observed in both mouse strains
(Fig. 1SD).
Our ﬁndings are consistent with the development of early stage of
PAH promoted by severe oxidation and ampliﬁed inﬂammatory re-
sponse in Prx2-/- mice exposed to 7-days hypoxia.
3.3. Prx2 plays an important role as cytoprotective system against hypoxia
induced PAH
In order to follow-up the generation of PAH in Prx2-/- mice, we
studied both mouse strains at diﬀerent time intervals between 0 to 7-
days hypoxia to identify the optimal window-time to analyze
Fig. 2. In Prx2-/- mice, hypoxia induces early stage pulmonary hypertension and is associated with activation of redox-related transcriptional factors. A. Comparison of Prx2-/-
with WT mice shows a sparse inﬂammatory inﬁltrate and an increased peribronchial edema in Prx2-/- mice (upper panel Hematoxylin Eosin ×250) and deposits of alpha actin in vascular
walls in Prx2-/- mice (lower panel Immunohistochemistry using anti alpha actin antibody × 600). B. Representative images of mitral inﬂow pattern recorded by Doppler echo imaging in
wildtype (WT) and Prx2-/- mice under hypoxia as in Fig. 1A. Lower panels. Average mitral valve deceleration time (left panel) and pulmonary acceleration time (PAT) to ejection time
(ET) ratio (right panel). *p<0.05 and **p< 0.01 WT vs Prx2-/- mice; #p<0.05 and ##p<0.01 hypoxia vs basal by one-way ANOVA followed by Newman-Keuls Multiple Comparison
test. The black dashed lines have been added to the graph to favor visual comparison between the white bars vs the black bars. C. Immunoblot analysis with speciﬁc antibodies against
peroxiredoxin-2 (Prx2) and thioredoxin-reductase 1 (Trdx) of lung wildtype (WT) and Prx2-/- mice under normoxia (N) exposed to hypoxia) for 10 h (10 h), 3 days (3D), 7 days (7D). One
representative gel from six with similar results is presented. Densitometric analysis of immunoblots is shown in Fig. 2SA. D. Immunoblot analysis with speciﬁc antibodies against phospho-
NF-kB (P-NF-kB), NF-kB, phospho-Nrf2 (P-Nrf2) and Nrf2 of lung wildtype (WT) and Prx2-/- mice under normoxia (N) and exposed to hypoxia (Hy) for 10 h (10 h), 3 days (3D), 7 days
(7D). One representative gel from six with similar results is presented. Densitometric analysis of immunoblots is shown in Fig. 2SB.
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mechanism(s) involved in development of PAH. BAL protein and leu-
kocyte count were signiﬁcantly increased in Prx2-/- mice during hy-
poxia at 10 h, 3 days and 7 days compared to wildtype animals (data
not shown).
Hypoxia markedly increased Prx2 expression in lung from wildtype
mice at 10 h, 3 days and 7 days of exposure (Fig. 2C; Fig. 2SA). This was
associated with time dependent increased expression of thioredoxin-
reductase, a Prx2 repairing system (Trdx; Fig. 2C; Fig. 2SA). The
modulation of Trdx expression during hypoxia even in the absence of
Prx2, may be possible related to the fact that Trdx is part of diﬀerent
NADPH-dependent pathways [19,40].
In Prx2-/- mice exposed to hypoxia, we observed a rapid and sus-
tained activation of Nrf2 in response to hypoxia, while there was a
reduction in activation of NF-kB (Fig. 2D, 2SB). Otherwise, wildtype
mice showed an early response of Nrf2 at 10 and 3-h hypoxia, partially
overlapping the activation of NF-kB observed at 3 and 7 days hypoxia
(Figs. 2D, 2SB). These data suggest that Nrf2 might be a precocious
back-up mechanism in response to hypoxia, which is early activated in
both mouse strains, but to higher extent in mice genetically lacking
Prx2.
Since pro-inﬂammatory cytokines are modulated by oxidation and
participates to the development of PAH [3,41,42], we evaluated IL1b
and IL6 expression in lung from both mouse strains during hypoxia. In
Prx2-/- mice, IL-1b mRNA levels were signiﬁcantly increased at 3 days
of hypoxia compared to wildtype animals, which displayed increased
IL-1b expression only at 7-days hypoxia (Fig. 3A). In Prx2-/- mice, lung
IL-6 mRNA expression was signiﬁcantly upregulated at 3 days of hy-
poxia followed by a decreased at 7 days of hypoxia to levels still higher
than those observed in wildtype mice (Fig. 3B). These data support an
earlier and ampliﬁed inﬂammatory response in Prx2-/- mice in response
to hypoxia compared to wildtype animals.
We then evaluated markers of pulmonary vascular remodeling (ET-
1, PDGF-B, ANP) and vascular endothelial activation (VCAM-1 and
ICAM-1). As shown in Fig. 3C, ET-1 expression was increased in both
mouse strains but to a higher extent in Prx2-/- mice compared to
wildtype; while PDGF-B levels increased earlier, reaching higher and
constant levels in Prx2-/- mice compared to wildtype during hypoxia.
VCAM-1 and ICAM-1 expression was similarly increased in both mouse
strains at 7 days hypoxia (Fig. 3D). Whereas, ANP levels were higher in
Prx2-/- mice than in wildtype animals exposed to prolonged hypoxia
(Fig. 3D).
Collectively, these data indicate that the absence of Prx2 accelerates
vascular activation and extra-cellular matrix remodeling, amplifying
inﬂammatory response and oxidation during hypoxia.
3.4. The absence of Prx2 is associated with endoplasmic reticulum (ER)
stress and up-regulation of ATF6
Studies in diﬀerent models of PAH have shown that hypoxia and/or
PDGF-B and /or ET-1 induce severe proteins damage, which promotes
endoplasmic reticulum stress (ER), triggering unfolded protein response
(UPR) system [10,11,13,43]. When the accumulation of damaged pro-
teins exceeds the ER capacity, ER stress leads to activation of autophagy
as adaptive mechanism to clear accumulated misfolded/unfolded pro-
teins [11,44]. UPR system is characterized by 3 branches: IRE, PERK
and ATF6, this latter has been reported to be mainly involved in PAH
[12,45]. As shown in Fig. 4A, ATF6, Chop and sXbp1 were up-regulated
in lung from Prx2-/- mice under normoxia compared to wildtype ani-
mals. Whereas, GADD34 was downregulated in Prx2-/- mice compared
to wildtype animals (Fig. 4A). In response to hypoxia, we observed
dynamic changes of the main UPR systems: (i) ATF6; (ii) GADD34 and
Chop, related to PERK and Xbp1, a component of IRE branch [10]. As
shown in Fig. 4B, increased mRNA levels of both Chop and Xbp1 were
observed at 10 h in Prx2-/- mice, while GADD34 was still signiﬁcantly
increased at 3-days hypoxia compared to normoxic Prx2-/- animals. In
chronically exposed Prx2-/- mice, ATF6 and sXbp1 mRNA levels were
again higher than in normoxia Prx2-/- animals (Fig. 4B). Wildtype an-
imals show an early signs of ER stress with up-regulation of ATF6 and
Xbp1 at 10-h hypoxia, with no major change in chronic hypoxia
(Fig. 4B). It is of note that in lung from wildtype mice, we found Prx2
organized in multimers, possible reﬂecting the acquisition of chaperone
like function (data not shown) [31,46,47].
These data indicate that the absence of Prx2 triggers ER stress
during hypoxia, contributing to the early appearance of PAH in Prx2-/-
mice.
3.5. PEP Prx2 treatment rescues prolonged hypoxia induced heart and lung
inﬂammatory vasculopathy and prevents ER stress
To address the question whether Prx2 plays a role in lung chronic
inﬂammatory disease, we ﬁrstly evaluated the impact of recombinant
fusion protein PEP Prx2 (1.5 mg/kg/day ip; 3 weeks) to both mouse
strains under room air condition. In normoxic Prx2-/- mice, PEP Prx2
treatment (i) prevented Nrf2 and NF-kB activation (Fig. 3SA); (ii) re-
duced HO-1 protein expression (Fig. 3SB); and (iii) decreased the levels
of ET-1, VCAM-1 and PDGF-B (Fig. 3SB). No major changes were ob-
served in wildtype animals (Fig. 3SA, 3SB). In order to evaluate whe-
ther the eﬀects of PEP Prx2 treatment were speciﬁc of Prx2 or related to
a general anti-oxidant eﬀect, we treated both mouse strains with NAC
(100 mg/kg/day for 3 weeks), a known anti-oxidant agent previously
used in other in vitro and in vivomodels of PAH [6,48]. No changes were
present in the levels of Nfr2 and NF-kB activation in Prx2-/- mice treated
with NAC, suggesting that the eﬀects of PEP Prx2 are peculiar of Prx2
and not only related to its general antioxidant eﬀects (data not shown).
In Prx2-/- mice exposed to 7 days hypoxia, PEP Prx2 treatment
signiﬁcantly reduced the hypoxia mediated diastolic dysfunction and
ameliorated RVSP, as suggested by the increased in PAT/ET ratio
(Fig. 4C, 4SA). In agreement, in heart from PEP Prx2 treated Prx2-/-
mice exposed to 7 days hypoxia, we found a reduction of ANP ex-
pression as well as of markers of vascular endothelial activation
(Fig. 4D). This was associated with a decrease in levels of SOD-1 and in
oxidation of proteins from heart of hypoxic Prx2-/- mice treated with
PEP Prx2 (Fig. 4SB). We found similar evidences of the beneﬁcial eﬀects
of PEP Prx2 on lung from Prx2-/- mice exposed to prolonged hypoxia. As
shown in Fig. 5A, PEP Prx2 promoted a signiﬁcant reduction in chronic
hypoxia induced increase of ANP, VCAM-1, ICAM-1 and PDGF-B levels
compared to vehicle treated Prx2-/- animals. In addition, PEP Prx2 de-
creased the hypoxia induced ATF6 expression, suggesting a possible
role of Prx2 as chaperone in agreement with the reduced expression of
classic chaperone HSP70 and 90 (Fig. 5B).
To better understand the role of Prx2 in development of PAH, we
chose to further study Prx2-/- mice at day 3 of hypoxia. This represents
the turning point in the imbalance between oxidation/anti-oxidant
activities and the activation of cellular defense mechanisms against
cytotoxic eﬀects of accumulation of damage proteins. Indeed, we found
a signiﬁcant increase in the amount of Prx2 dimers in lung from wild-
type after 3 days hypoxia compared to normoxic wildtype animals
(Fig. 4SC), supporting the role of Prx2 as H2O2 sensor generated during
hypoxia as previously shown in other models [34,49].
3.6. In Prx2-/- mice, PEP Prx2 prevents the hypoxia induced oxidative stress
and reduces inﬂammatory vascular activation and extracellular matrix
remodeling
PEP Prx2 administration prevented the hypoxia induced increased
in BAL protein and leukocyte content in both mouse strains (Fig. 4SD).
This was associated with a marked reduction in protein oxidation state
in both mouse strains exposed to 3 days hypoxia and treated with PEP
Prx2, supporting the local anti-oxidant eﬀect of exogenous PEP Prx2
treatment during hypoxia stress (Fig. 5C). In agreement, we found that
PEP Prx2 administration prevented the hypoxia induced Nrf2 and NF-
kB activation in both mouse strains (Fig. 5D, 5SA). This was paralleled
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by the reduction in HO-1, IL-6, ET-1, VCAM-1 and PDGF-B (Fig. 6A).
These data suggest that PEP Prx2 treatment during hypoxia is able
to (i) decrease local pulmonary inﬂammation and oxidation, (ii) reduce
systemic inﬂammatory response; (iii) beneﬁcially aﬀect hypoxia ab-
normalities in pulmonary vascular leakage; and (iv) prevent hypoxia
activation of redox-sensitive transcriptional factors Nrf2 and NF-kB.
3.7. PEP Prx2 alleviates ER stress and down-regulates autophagy in Prx2-/-
mice exposed to hypoxia
As shown in Fig. 6B, PEP Prx2 signiﬁcantly down-regulated G-
ADD34 in lung from Prx2-/- mice compared to vehicle treated animals.
This was associated with a marked decrease in HSP70 and 90 expres-
sion in lung from both mouse strains exposed to 3 days hypoxia and
treated with PEP Prx2 (Fig. 6C). This is agreement with previous reports
on preventing PAH development by blocking ER stress with exogenous
chemical chaperones [12].
Since a link between ER stress and activation of autophagy has been
proposed to deal the accumulation of damaged proteins [10,44], we
evaluated key elements of autophagy machinery and the eﬀects of PEP
Prx2 treatment in both mouse strains at 3 days hypoxia. Based on re-
vision of the literature, we chose to analyze the expression of (i) au-
tophagy related proteins ULk1 that is required for initiation of autop-
hagy; (ii) LC3 I/II, a coordinator of phagosomal membranes and (iii)
p62, a key cargo protein and component of inclusion bodies; and (iv)
pro-caspase 3/caspase 3, involved in digestion of damaged proteins
[9,50–52]. As shown in Fig. 7A, normoxic Prx2-/- mice showed in-
creased LC3-II formation associated with increased expression of Ulk1
and p62 compared to wildtype mice. This was associated with higher
expression of pro-caspase 3/caspase 3, indicating an activation of au-
tophagy to clear intracellular oxidative damaged proteins in Prx2-/-
mice. In both mouse strains, hypoxia markedly activated autophagy as
supported by increased LC3I/II expression, consumption of Ulk1 and
reduction of p62, suggesting a clearance of p62 positive inclusion
Fig. 3. In Prx2-/- mice, hypoxia is associated with ampliﬁed inﬂammatory response, vascular activation and increased expression of PDGF-B, a marker of extracellular matrix
remodeling. A-B. IL-1b (A) and IL-6 (B) mRNA levels in lung tissues (normalized to GADPH) wildtype (WT) and Prx2-/- mice under normoxia (N) and exposed to hypoxia for 10 h (10 h),
3 days (3D), 7 days (7D). *p< 0.05 compared to wildtype; ^ p value< 0.05 compared to normoxic mice. Each sample is a pool from 5 mice. Representative of three independent
experiments. C. Upper panel. Immunoblot analysis with speciﬁc antibodies against endothelin-1 (ET-1) and platelet derived growth factor-B (PDGF-B) of lung from wildtype (WT) and
Prx2-/- mice under normoxia (N) and exposed to hypoxia for 10 h (10 h), 3 days (3D), 7 days (7D). One representative gel from six with similar results is presented. Lower panel. Relative
quantiﬁcation of immunoreactivity (DU: Density Units) of ET-1 and PDGF-B in lung from wildtype (WT) and Prx2-/- mice under normoxia (N) and exposed to hypoxia for 10 h (10 h), 3
days (3D), 7 days (7D). Data are shown as means± SD (n= 6). *p<0.05 compared to wildtype; ^ p< 0.05 compared to normoxic mice. The grey area highlights the changes in the ET-1
and PDGF-B expression in the mouse strains at 3 days hypoxia. D. Upper panel. Immunoblot analysis with speciﬁc antibodies against atrial natriuretic peptide (ANP), vascular adhesion
molecule -1 (VCAM-1) and intracellular adhesion-molecule- 1 (ICAM-1) of lung from wildtype (WT) and Prx2-/- mice under normoxia (lane 1 and 2) and exposed to 7 days (7D) hypoxia.
One representative gel from six with similar results is presented. Lower panel. Relative quantiﬁcation (DU: Density Units) of immunoreactivity of ANP, VCAM-1, ICAM-1 in lung from
wildtype (WT) and Prx2-/- mice under normoxia and exposed to 7 days (7D) hypoxia. Data are shown as means± SD (n = 6); *p< 0.05 compared to wildtype; ^ p< 0.05 compared to
normoxic mice.
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bodies containing damaged proteins (Fig. 7A). It is of note that the pro-
caspase/caspase 3 ratio was also increased in both mouse models ex-
posed to hypoxia, but to higher extent in Prx2-/- mice compared to
wildtype (Fig. 7A).
As a proof of concept that Prx2 is important in the crossroad be-
tween hypoxia induced oxidation and autophagy, we evaluated the
eﬀects of PEP Prx2 treatment on autophagy in mice exposed to 3 days
hypoxia. As shown in Fig. 7A, PEP Prx2 administration rescued the
hypoxia induced activation of autophagy. These data indicate that Prx2
acts as multimodal cytoprotective system and is important to prevent
the development of PAH.
4. Discussion
Here, we ﬁrstly show the novel role of Prx2 as lung multimodal
cytoprotector against hypoxia induced PAH. Our data also indicate that
Prx2 is required in management of the physiologic oxidation in lung
under room air condition. In fact, normoxic Prx2-/- mice show we lung
chronic inﬂammatory vasculopathy and vascular dysfunction, asso-
ciated with activation of extracellular matrix remodeling. This is in
agreement with previous studies in mouse models genetically lacking
other anti-oxidant systems such as SOD-1, which show increased sus-
ceptibility to both acute and chronic lung injury [53–55].
Fig. 4. Hypoxia induces ER stress in Prx2-/- mice and PEP Prx2 administration prevents the hypoxia induced diastolic dysfunction with reduction of inﬂammatory vascu-
lopathy. A-B. ATF6, CHOP, GADD34, sXBP1 mRNA levels in lung tissues wildtype (WT) and Prx2-/- mice under normoxia (N) *p< 0.05 compared to wildtype. Each sample is a pool from
5 mice. Representative of three independent experiments (A). ATF6, CHOP, GADD34, sXBP1 mRNA levels in lung tissues (normalized to GADPH) wildtype (WT) and Prx2-/- mice exposed
to hypoxia for 10 h (10 h), 3 days (3D), 7 days (7D). Each sample is a pool from 5 mice. (B) ATF6 *p<0.05 for WT mice 10 h vs 3D; 10 h vs 7D. ATF6 *p< 0.05 for Prx2-/- mice 10 h vs
3D; ^ p< 0.05 for WT mice 7D vs Prx2-/- mice 7D. CHOP *p<0.05 for WT mice 10 h vs 3D; 10 h vs 7D. CHOP *p<0.05 for Prx2-/- mice 10 h vs 3D; 10 h vs 7D; ^ p< 0.05 for WT mice
10 h vs Prx2-/- mice 10 h. GADD34 *p<0.05 for WT mice 10 h vs 3D; 10 h vs 7D. GADD34 *p<0.05 for Prx2-/- mice 10 h vs 3D. sXbp1 *p< 0.05 for WT mice 10 h vs 3D; 10 h vs 7D. ^
p<0.05 for WT mice 7D vs Prx2-/- mice 3D and 7D. sXbp1 *p< 0.05 for Prx2-/- mice 10 h vs 3D. ^ p< 0.05 for WT mice 7D vs Prx2-/- mice 7D. C. Average mitral valve deceleration time
(left panel) and pulmonary acceleration time (PAT) to ejection time (ET) ratio (right panel); *p< 0.05 vehicle treated Prx2-/- mice vs PEP Prx2 treated Prx2-/- mice; by one-way ANOVA
followed by Newman-Keuls Multiple Comparison test. The black dashed lines have been added to the graph to favor visual comparison between the white bars vs the black bars.
Representative images of mitral inﬂow pattern recorded by Doppler echo imaging in Prx2-/- mice treated with PEP Prx2 are shown in Fig. 4SA. D. Immunoblot analysis with speciﬁc
antibodies against atrial natriuretic peptide (ANP), vascular adhesion molecule -1 (VCAM-1), intracellular adhesion-molecule- 1 (ICAM-1) and superoxide dismutase-1 (SOD-1) of heart
from Prx2-/- mice under normoxia (lane 1) and exposed to 7 days (7D) hypoxia treated with either vehicle or PEP Prx2. One representative gel from six with similar results is presented;
GAPDH was used as protein loading control. Right panel. Relative quantiﬁcation of immunoreactivity (DU: Density Units) of ANP, VCAM-1, ICAM-1, SOD1 of heart from Prx2-/- mice
under normoxia and exposed to 7 days (7D) hypoxia treated with either vehicle or PEP Prx2. Data are presented as means± SD (n = 6); ^p< 0.05 compared to Prx2-/- normoxic mice; °
p<005 compared to vehicle treated mice.
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Prx2-/- mice exposed to prolonged hypoxia developed signs of PAH,
combined with inﬂammatory vasculopathy, sustained by high ET-1
expression and increased PDGF-B levels, as marker of extracellular
matrix remodeling. Both molecules have been reported to accelerate the
development of hypoxia induce PAH [30,39]. The increase ANP lung
and heart expression indicates an attempt of endogenous system to
induce pulmonary vaso-relaxation and to modulate lung and heart
vascular remodeling in response to hypoxia [56,57]. This was co-
ordinated by hypoxia induced activation of acute phase related tran-
scriptional factors: Nrf2 and NF-kB in both mouse strains. The early and
higher activation of Nrf2 in Prx2-/- mice compared to wildtype animals,
supports the role of Nrf2 as back-up mechanism against severe oxida-
tion in mice genetically lacking Prx2 [19]. Whereas, NF-kB seemed to
be more important in prolonged hypoxia for wildtype mice compared to
Prx2-/- animals. The rescue experiments with PEP Prx2 corroborate the
importance of Prx2 in the functional cascade activated in response to
hypoxia.
In this scenario, the absence of Prx2 favors ER stress with the ac-
tivation of autophagy, as important mechanisms to deal with the
accumulation of cytotoxic damaged proteins triggered by hypoxia and
oxidation [10,44]. ER stress activates the UPR system, which is divided
into three branches: ATF6, PERK and IRE1 [10,13]. In Prx2-/- mice,
ATF6 was up-regulated in lung from animals under normoxia and after
prolonged hypoxia. Whereas, GADD34, part of PERK branch, was early
up-regulated at 3 days hypoxia in Prx2-/- mice. This indicate that the
absence of Prx2 favors ER stress most likely due to a reduction of en-
dogenous chaperone power beside the increased expression of classic
heat shock proteins such as HSP70 and 90 in response to hypoxia. PEP
Prx2 alleviated ER stress and prevented the hypoxia induced up-reg-
ulation of UPR system, in agreement with previous report on exogenous
chemical chaperones, reducing ER stress and preventing the develop-
ment of PAH [12,13]. It is of interest to note that previous reports have
shown that PDGF-B and/or ET- activates UPR [13,43]. In our model,
the absence of Prx2 resulted in high levels of PDGF-B and ET1 that
potentiate the hypoxia induced activation of UPR system. The rescue
experiments with PEP Prx2 corroborate the pivotal role of Prx2 in lung
homeostasis.
The behavior of defensive autophagy in Prx2-/- mice exposed to
Fig. 5. PEP Prx2 administration prevents lung vascular remodeling and alleviates ER stress induced by prolonged hypoxia. A. Immunoblot analysis with speciﬁc antibodies
against atrial natriuretic peptide (ANP), vascular adhesion molecule -1 (VCAM-1), intracellular adhesion-molecule- 1 (ICAM-1) and PDGF-B of lung from Prx2-/- mice under normoxia
(lane 1) and exposed to 7 days (7D) hypoxia treated with either vehicle or PEP Prx2. One representative gel from six with similar results is presented; GAPDH was used as protein loading
control. Right panel. Relative quantiﬁcation of immunoreactivity (DU: Density Units) of ANP, VCAM-1, ICAM-1 and PDGF-B in lung from Prx2-/- mice under normoxia (lane 1) and
exposed to 7 days (7D) hypoxia treated with either vehicle or PEP Prx2. Data are shown as means± SD (n = 6); ^ p< 0.05 compared to Prx2-/- normoxic mice; ° p< 0.05 compared to
Prx2-/- treated with vehicle. B. Immunoblot analysis with speciﬁc antibodies against activating transcriptional factor-6 (ATF6), heat shock protein 70 (HSP70) and heat shock protein 90
(HSP90) of lung from Prx2-/- mice under normoxia (lane 1) and exposed to 7 days (7D) hypoxia treated with either vehicle or PEP Prx2. One representative gel from six with similar results
is presented; GAPDH was used as protein loading control. Right panel. Relative quantiﬁcation of immunoreactivity (DU: Density Units) of ATF6, HSP70 and HSP90. Data are shown as
means± SD (n = 6); ^ p<0.05 compared to Prx2-/- normoxic mice; ° p<0.05 compared to Prx2-/- treated with vehicle. C. The carbonylated proteins (1 μg) were detected by treating
with DNPH and blotted with anti-DNP antibody. Right panel. Quantiﬁcation of band area was performed by densitometry and expressed as % of WT. The data are presented as
means± SD of at least three independent experiments *p<0.05 compared to WT; ° p< 0.05 compared to vehicle treated mice (n= 3). D. Immunoblot analysis with speciﬁc antibodies
against phospho-NF-kB (P-NF-kB), NF-kB, phospho-Nrf2 (P-Nrf2) and Nrf2 of lung from wildtype (WT) and Prx2-/- mice under normoxic condition treated with either vehicle or
penetrating peptide fusion protein peroxiredoxin-2 (PEP Prx2). One representative gel from six with similar results is presented. Densitometric analysis of immunoblots is shown in
Fig. 5SA.
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hypoxia is strongly linked to ER stress in the absence of Prx2. Treatment
with PEP Prx2 reduced ER stress and switched-oﬀ autophagy as sup-
ported by the reduction in LC3II and accumulation of p62 (Fig. 6A).
This was parallel by a decrease of hypoxia induced HSP70 and 90 ex-
pression and down-regulation of GADD34 and ATF6 levels in PEP Prx2
treated Prx2-/- mice exposed respectively to 3 and 7 days hypoxia.
Collectively, our data indicate that PEP Prx2 has a multimodal ac-
tion targeting: (i) the inﬂammatory response; (ii) vascular and extra-
cellular matrix remodeling, (iii) ER stress and autophagy (Fig. 7B). The
correction of the imbalance between oxidation and anti-oxidant sys-
tems combined with a chaperone like function exerted by Prx2 might
interrupt the vicious circle, established between oxidation-chronic in-
ﬂammation with ER stress and activation of autophagy towards the
generation of PAH (Fig. 7B).
In conclusion, we have ﬁrstly highlighted the novel pivotal role of
Prx2 in preventing PAH induced by hypoxia. The high bio-complexity
of PAH requires multimodal therapeutic approaches, which simulta-
neously act on diﬀerent targets involved in its pathogenesis. Our data
collectively support a rationale for considering Prx2 as novel
therapeutic option in treatment of the early phase of PAH.
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Fig. 6. PEP Prx2 administration reduces ER stress and prevents chaperone expression in the early phase of hypoxia. A. Immunoblot analysis with speciﬁc antibodies against IL-6,
endothelin-1 (ET-1), vascular cell adhesion molecule-1 (VCAM-1), platelet derived growth factor-B (PDGF-B) of lung from wildtype (WT) and Prx2-/- mice under normoxic condition
treated (lane 1–2) or exposed to hypoxia (3D) and treated with either vehicle or penetrating peptide fusion protein peroxiredoxin-2 (PEP Prx2). One representative gel from six with
similar results is presented. GAPDH was used as loading control. Right panel. Relative quantiﬁcation of immunoreactivity (DU: Density Units) of IL-6, ET-1, VCAM-1 and PDGF-B. Data
are shown as means± SD (n= 6). *p< 0.05 compared to wildtype; ^p<0.05 compared to normoxic mice; °p< 005 compared to vehicle treated mice. B. GADD34 levels in lung tissues
(normalized to GADPH) wildtype (WT) and Prx2-/- mice treated with either vehicle or penetrating peptide fusion protein peroxiredoxin-2 (PEP Prx2) exposed to hypoxia for 3D *p<0.05
compared to wildtype. Each sample is a pool from 5 mice. Representative of three independent experiments. C. Immunoblot analysis with speciﬁc antibodies against heat shock protein-
70 (HSP70) and -90 (HSP90) of lung from wildtype (WT) and Prx2-/- mice under normoxic condition treated (lane 1–2) or exposed to hypoxia (3D) and treated with either vehicle or
penetrating peptide fusion protein peroxiredoxin-2 (PEP Prx2). One representative gel from six with similar results is presented. GAPDH was used as loading control. Right panel. C.
Relative quantiﬁcation of immunoreactivity (DU: Density Units) of HSP70 and HSP 90. Data are shown as means± SD (n = 6); ^p< 0.05 compared to normoxic mice; °p<005
compared to vehicle treated mice.
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a b s t r a c t
The data presented in this article are related to the research paper
entitled “peroxiredoxin-2 plays a pivotal role as multimodal
cytoprotector in the early phase of pulmonary hypertension”
(Federti et al., 2017) [1]. Data show that the absence of peroxir-
edoxin-2 (Prx2) is associated with increased lung oxidation and
pulmonary vascular endothelial dysfunction. Prx2−/− mice dis-
played activation of the redox-sensitive transcriptional factors, NF-
kB and Nrf2, and increased expression of cytoprotective system
such as heme-oxygenase-1 (HO-1). We also noted increased
expression of both markers of vascular activation and extracellular
matrix remodeling. The administration of the recombinant fusion
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protein PEP Prx2 reduced the activation of NF-kB and Nrf2 and was
paralleled by a decrease in HO-1 and in vascular endothelial
abnormal activation. Prolonged hypoxia was used to trigger pul-
monary artery hypertension (PAH). Prx2−/− precociously devel-
oped PAH compared to wildtype animals.
& 2017 Published by Elsevier Inc. This is an open access article
under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Speciﬁcations Table
Subject area Health Sciences
More speciﬁc sub-
ject area
Oxidation, peroxiredoxin-2 and pulmonary artery hypertension
Type of data Text ﬁle, Figures
How data was
acquired
Image Quant Las Mini 4000 Digital Imaging System (GE Healthcare Life
Sciences). Densitometric analyses were performed using the ImageQuant TL
software (GE Healthcare Life Sciences).
Data format Raw analyzed
Experimental
factors
C57B6/2J as wildtype mice and Prx2−/− mice
Experimental
features
Protein expression was analyzed by Western-blotting.
Oxidized proteins were revealed by the Oxyblot Protein Oxidation Detection
Kit (EMD Millipore); MDA pulmonary levels were evaluated by Oxiselect
MDA Immunoblot kit (GE Healthcare).
Data source
location
Dept. of Medicine, LURM, Policlinico GB Rossi, University of Verona and AOUI
Verona; Verona; Italy
Data accessibility Data are available with this article
Value of the data
 Our data show that the absence of Prx2 is associated with increased lung oxidation and abnormal
pulmonary vascular leakage.
 Treatment with fusion protein PEP Prx2 prevents the activation of redox related transcriptional
factors and modulates anti-oxidant systems in both wildtype and Prx2−/− mice.
 PEP Prx2 signiﬁcantly reduces protein oxidation in lung from exposed to prolonged hypoxia used
to trigger pulmonary artery hypertension.
1. Data
Data show increased lung oxidation (Fig. 1A) and abnormal pulmonary vascular leakage in the
absence of Prx2 (Fig. 1B). This was paralleled by the activation of redox-sensitive transcriptional
factors NF-kB and Nrf2 in lung from Prx2−/− compared to wildtype animals (Fig. 2A). Indeed, in Prx2−/
− we observed (i) increased expression of heme-oxygenase 1 (HO-1), a Nrf2 related cytoprotective
system; (ii) markers of vascular endothelial activation such as endothelin-1 (ET-1) and vascular cell
adhesion molecule -1 (VCAM-1) and (iii) marker of extracellular matrix remodeling as the platelet
growth factor- B (PDGF-B) that has been recently function linked to the development of pulmonary
artery hypertension (Fig. 2B). To verify the role of Prx2 as important anti-oxidant system in pul-
monary homeostasis, we administrated the recombinant fusion protein PEP Prx2 at the dosage of
3 mg/Kg/d ip or vehicle for 4 weeks [1–3]. As shown in Fig. 2, PEP Prx2 signiﬁcantly reduced both
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NF-kB and Nrf2 activation in lung from Prx2−/− and decreased the expression of both HO-1 and
markers of vascular endothelial activation or extracellular matrix remodeling.
Using prolonged hypoxia to trigger pulmonary artery hypertension, we observed severe lung
pathologic damage and the precocious development of pulmonary artery hypertension in Prx2−/−
mice compared to wildtype animals [4–6]. This was associated with (i) marked activation of redox-
related transcriptional factors; (ii) severe endoplasmic-reticulum stress with activation of the
unfolded protein response (UPR) system; and (iii) activation of autophagy [1].
PEP Prx2 treatment prevented the hypoxia induced protein oxidation in mice exposed to pro-
longed hypoxia (7 days; Fig. 3A) and reduced the hypoxia induced increased expression of HO-1 in
both mouse strains exposed to 3 days hypoxia (Fig. 3B). Collectively, these data indicate the important
role of Prx2 in lung homeostasis against hypoxia, a known trigger of lung injury.
2. Experimental design, materials and methods
2.1. MDA assay
MDA was determined as previously reported [7,8].
2.2. Measurement of BAL protein content
2.2.1. Bronchoalveolar lavage assay
Bronchoalveolar lavage (BAL) ﬂuids were collected and cellular contents were recovered by cen-
trifugation and counted by microcytometry as previously reported [6,9].
Fig. 1. A. 10 μg of soluble proteins of lung homogenate were tested for MDA-protein adducts. Quantiﬁcation of band area was
performed by densitometry and expressed as % of WT. The data are presented as means 7 SD of at least three independent
experiments; statistically signiﬁcant differences were determined by Student's t-test. *p o 0.05. B. Upper panel. BAL protein
content fromwildtype (WT) and Prx2−/−mice under normoxic condition. Data are presented as means7 SD (n ¼ 6; *p o 0.05
compared to WT mice). Lower panel. BAL leukocyte content from wildtype (WT) and Prx2−/− mice under normoxic condition.
Data are presented as means 7 SD (n ¼ 6; *p o 0.05 compared to WT mice).
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2.2.2. Immunoblot analysis
Frozen lung from each studied group were homogenized and lysed with iced lyses buffer as
previously described [3,10,11]. Gels were transferred to nitrocellulose membranes for immuno-blot
analysis with speciﬁc antibody: anti-NFkB-phospho-S536 (93H1) (Cell Signaling Technology, Leiden,
NL); anti-NFkB p65 (C22B4) (Cell Signaling Technology, Leiden, NL); anti-Nrf2-phospho-S40 (Clone
EP1809Y, AbCam, Cambridge, UK); anti-Nrf2 (AbCam, Cambridge, UK); anti-Heme Oxygenase-1 (HO-
1) (Santa Cruz Biotechnology, Heidelberg, Germany), anti-Endothelin-1 (ET-1) (Santa Cruz Bio-
technology, Heidelberg, Germany); anti-VCAM-1 (R and D Systems, Minneapolis, MN, USA); anti-
PDGF-B (AbCam, Cambridge, UK); anti-GAPDH (Sigma Aldrich, Saint Louis, MO, USA) was used as
loading control. Images were acquired using Image Quant Las Mini 4000 Digital Imaging System (GE
Healthcare Life Sciences). Densitometric analyses were performed using the ImageQuant TL software
(GE Healthcare Life Sciences) [11].
Fig. 2. A. Immunoblot analysis with speciﬁc antibodies against phospho-Nrf2 (P-Nrf2), Nrf2 phospho-NF-kB (P-NF-kB) and NF-
kB of lung fromwildtype (WT) and Prx2−/−mice under normoxic condition. One representative gel from six with similar results
is presented. Right panel. Relative quantiﬁcation of immunoreactivity (DU: Density Units) of phospho-NF-kB (P-NF-kB), NF-k,
phospho-Nrf2 (P-Nrf2) and Nrf2 of lung from wildtype (WT) and Prx2−/− mice under normoxic condition treated with either
vehicle or penetrating peptide fusion protein peroxiredoxin-2 (PEP Prx2). Data are shown as means 7 SD (n ¼ 6). *p o 0.05
compared to wildtype; °p o 005 compared to vehicle treated mice. B. Immunoblot analysis with speciﬁc antibodies against
heme-oxygenase 1 (HO-1), endothelin-1 (ET-1), vascular cell adhesion molecule-1 (VCAM-1), under normoxic condition
treated with either vehicle or penetrating peptide fusion protein peroxiredoxin-2 (PEP Prx2). One representative gel from six
with similar results is presented. Right panel. Relative quantiﬁcation of immunoreactivity (DU: Density Units) of heme-oxy-
genase 1 (HO-1), endothelin-1 (ET-1), vascular cell adhesion molecule-1 (VCAM-1), platelet derived growth factor-B (PDGF-B)
of lung from wildtype (WT) and Prx2−/− mice under normoxic condition treated with either vehicle or penetrating peptide
fusion protein peroxiredoxin-2 (PEP Prx2). Data are shown as means 7 SD (n ¼ 6). *p o 0.05 compared to wildtype; °p o
0.05 compared to vehicle treated mice.
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2.2.3. Measurement of lung protein oxidation
Oxidized proteins were revealed by the Oxyblot Protein Oxidation Detection Kit (EMD Millipore).
In brief, the soluble protein extracts were derivatized to 2,4-dinitrophenylhydrazone (DNP) and 1 µg
was loaded on 12% SDS-PAGE, blotted and incubated with an anti-DNP antibody, followed by an HRP
conjugated secondary antibody. The bound activity was revealed by ECL (GE Healthcare). Oxidized
proteins were revealed by the Oxyblot Protein Oxidation Detection Kit (EMD Millipore). In brief, the
soluble protein extracts were derivatized to 2,4-dinitrophenylhydrazone (DNP) and 1 ug was loaded
on 12% SDS-PAGE, blotted and incubated with an anti-DNP antibody, followed by an HRP conjugated
secondary antibody. The bound activity was revealed by ECL (GE Healthcare) [12–14].
2.2.4. Generation of recombinant-PEP Prx2 fusion protein (PEP Prx2)
The fusion protein PEP Prx2 was generated as previously reported [2,3].
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Fig. 3. A. The carbonylated proteins (1 ug) from lung of Prx2−/− mice under normoxic condition or exposed to 7 days (7D)
hypoxia/reoxygenation stress (H/R) treated with either vehicle or penetrating peptide fusion protein peroxiredoxin-2 (PEP
Prx2) at the dosage of 3 mg/Kg/d ip or vehicle for 4 weeks before and during hypoxia (8% oxygen for 7 days). Right panel.
Quantiﬁcation of band area was performed by densitometry and expressed as % of Prx2 under normoxia. The data are pre-
sented as means 7 SD of at least three independent experiments; ^p o 0.05 compared to Prx2−/− normoxic mice; °p o 005
compared to vehicle treated mice. (n ¼ 3). B. Immunoblot analysis with speciﬁc antibodies against heme-oxygenase-1 (HO-1)
of lung from wildtype (WT) and Prx2−/− mice under normoxic condition or exposed to 3 days (3D) hypoxia/reoxygenation
stress (H/R) treated with either vehicle or penetrating peptide fusion protein peroxiredoxin-2 (PEP Prx2) at the dosage of 3 mg/
Kg/d ip or vehicle for 4 weeks before and during hypoxia (8% oxygen for 3 days). One representative gel from ﬁve with similar
results is presented. Lower panel. Relative quantiﬁcation of immunoreactivity (DU: Density Units) of heme-oxygenase 1 of lung
fromwildtype (WT) and Prx2−/− mice under normoxic condition or exposed to 3 days (3D) hypoxia/reoxygenation stress (H/R)
treated with either vehicle or PEP Prx2. Data are presented as means 7 SD of at least ﬁve independent experiments; *p o 0.05
compared to wildtype; ^p o 0.05 compared to Prx2−/− normoxic mice; °p o 005 compared to vehicle treated mice. (n ¼ 5).
E. Federti et al. / Data in Brief 15 (2017) 376–381380
Transparency document. Supplementary material
Transparency data associated with this article can be found in the online version at http://dx.doi.
org/10.1016/j.dib.2017.09.062.
References
[1] E. Federti, A. Matte, A. Ghigo, I. Andolfo, C. James, A. Siciliano, C. Leboeuf, A. Janin, F. Manna, S.Y. Choi, A. Iolascon,
E. Beneduce, D. Melisi, D.W. Kim, S. Levi, L. De Franceschi, Peroxiredoxin-2 plays a pivotal role as multimodal cytoprotector
in the early phase of pulmonary hypertension, Free Radic. Biol. Med. (2017).
[2] A. Matte, L. De Falco, A. Iolascon, N. Mohandas, X. An, A. Siciliano, C. Leboeuf, A. Janin, M. Bruno, S.Y. Choi, D.W. Kim, L. De
Franceschi, The interplay between peroxiredoxin-2 and nuclear factor-erythroid 2 is important in limiting oxidative
mediated dysfunction in beta-thalassemic erythropoiesis, Antioxid. Redox Signal. 23 (2015) 1284–1297.
[3] A. Matte, L. De Falco, E. Federti, A. Cozzi, A. Iolascon, S. Levi, N. Mohandas, A. Zamo, M. Bruno, C. Leboeuf, A. Janin,
A. Siciliano, T. Ganz, G. Federico, F. Carlomagno, S. Mueller, I. Silva, C. Carbone, D. Melisi, D.W. Kim, S.Y. Choi, L, D. E. F,
Peroxiredoxin-2: a novel regulator of iron homeostasis in ineffective erythropoiesis, Antioxid. Redox Signal. (2017).
[4] L. de Franceschi, A. Baron, A. Scarpa, C. Adrie, A. Janin, S. Barbi, J. Kister, P. Rouyer-Fessard, R. Corrocher, P. Leboulch,
Y. Beuzard, Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-speciﬁc lung injury induced by
hypoxia/reoxygenation, Blood 102 (2003) 1087–1096.
[5] L. De Franceschi, O.S. Platt, G. Malpeli, A. Janin, A. Scarpa, C. Leboeuf, Y. Beuzard, E. Payen, C. Brugnara, Protective effects of
phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell
mice, FASEB J. 22 (2008) 1849–1860.
[6] B.T. Kalish, A. Matte, I. Andolfo, A. Iolascon, O. Weinberg, A. Ghigo, J. Cimino, A. Siciliano, E. Hirsch, E. Federti, M. Puder,
C. Brugnara, L. De Franceschi, Dietary omega-3 fatty acids protect against vasculopathy in a transgenic mouse model of
sickle cell disease, Haematologica 100 (2015) 870–880.
[7] F. Maccarinelli, A. Pagani, A. Cozzi, F. Codazzi, G. Di Giacomo, S. Capoccia, S. Rapino, D. Finazzi, L.S. Politi, F. Cirulli,
M. Giorgio, O. Cremona, F. Grohovaz, S. Levi, A novel neuroferritinopathy mouse model (FTL 498InsTC) shows progressive
brain iron dysregulation, morphological signs of early neurodegeneration and motor coordination deﬁcits, Neurobiol. Dis.
81 (2015) 119–133.
[8] A. Matte, P.S. Low, F. Turrini, M. Bertoldi, M.E. Campanella, D. Spano, A. Pantaleo, A. Siciliano, L. De Franceschi, Peroxir-
edoxin-2 expression is increased in beta-thalassemic mouse red cells but is displaced from the membrane as a marker of
oxidative stress, Free Radic. Biol. Med. 49 (2010) 457–466.
[9] L. de Franceschi, G. Malpeli, A. Scarpa, A. Janin, E.M. Muchitsch, P. Roncada, C. Leboeuf, R. Corrocher, Y. Beuzard,
C. Brugnara, Protective effects of S-nitrosoalbumin on lung injury induced by hypoxia-reoxygenation in mouse model of
sickle cell disease, Am. J. Physiol. Lung Cell Mol. Physiol. 291 (2006) L457–L465.
[10] R. Bellelli, G. Federico, A. Matte, D. Colecchia, A. Iolascon, M. Chiariello, M. Santoro, L. De Franceschi, F. Carlomagno, NCOA4
deﬁciency impairs systemic iron homeostasis, Cell Rep. 14 (2016) 411–421.
[11] F. Lupo, E. Tibaldi, A. Matte, A.K. Sharma, A.M. Brunati, S.L. Alper, C. Zancanaro, D. Benati, A. Siciliano, M. Bertoldi, F. Zonta,
A. Storch, R.H. Walker, A. Danek, B. Bader, A. Hermann, L. De Franceschi, A new molecular link between defective
autophagy and erythroid abnormalities in chorea-acanthocytosis, Blood 128 (2016) 2976–2987.
[12] S.S. Franco, L. De Falco, S. Ghaffari, C. Brugnara, D.A. Sinclair, A. Matte, A. Iolascon, N. Mohandas, M. Bertoldi, X. An,
A. Siciliano, P. Rimmele, M.D. Cappellini, S. Michan, E. Zoratti, J. Anne, L. De Franceschi, Resveratrol accelerates erythroid
maturation by activation of FoxO3 and ameliorates anemia in beta-thalassemic mice, Haematologica 99 (2014) 267–275.
[13] F. Lupo, R. Russo, A. Iolascon, D. Ieluzzi, A. Siciliano, P. Toniutto, A. Matte, S. Piovesan, E. Raffetti, F. Turrini, D. Dissegna,
F. Donato, A. Alberti, V. Zuliani, G. Fattovich, L. De Franceschi, Protease inhibitors-based therapy induces acquired
spherocytic-like anaemia and ineffective erythropoiesis in chronic hepatitis C virus patients, Liver Int. 36 (2016) 49–58.
[14] L. de Franceschi, F. Turrini, M. Honczarenko, K. Ayi, A. Rivera, M.D. Fleming, T. Law, F. Mannu, F.A. Kuypers, A. Bast, W.J. van
der Vijgh, C. Brugnara, in vivo reduction of erythrocyte oxidant stress in a murine model of beta-thalassemia, Haema-
tologica 89 (2004) 1287–1298.
E. Federti et al. / Data in Brief 15 (2017) 376–381 381
 1 
59th Congress of the American Society of Hematology, December 2017, Atlanta, Georgia 
FYN KINASE IS INVOLVED IN EPO RECEPTOR SIGNALING AND IS REQUIRED 
TO HARMONIZE THE RESPONSE TO OXIDATION  
 
Elisabetta Beneduce, Alessandro Matte, Luigia De Falco, Serge Cedrick Mbiandijeu Toya, 
Emanuela Tolosano, Deborah Chiabrando, Angela Siciliano, Achille Iolascon, Mohandas 
Narla, Lucia De Franceschi 
 
CEINGE and Dept. of Biochemistry, Federico II University, Naples; Italy 
New York Blood Center, NY, USA 
Dept. Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy 
 
 
Erythropoiesis is a complex multistep process during which committed erythroid 
progenitors undergo terminal differentiation to produce circulating mature red cells. 
Erythroid differentiation is characterized by the production of reactive oxygen species 
(ROS) both in response to erythropoietin (EPO) and to the large amount of iron 
imported into the cells for heme biosynthesis. During erythropoiesis, ROS might 
function as second messenger by modulating intracellular signaling pathways. Fyn, 
an Src kinase, has been previously reported to participate in signaling pathways in 
response to ROS in various cell types. Here, we explore the potential contribution of 
Fyn to normal and stress erythropoiesis by studying 2-4 months-old Fyn knockout 
mouse strain (Fyn-/-) and C57B6/2J as wild-type controls. Fyn-/- mice showed a mild 
compensated microcytic anemia associated with signs of dyserythropoiesis. 
Increased ROS levels and Annexin-V+ cells were presented in all Fyn-/- erythroblast 
subpopulations compared to wild-type, suggesting a possible reduction in the 
efficiency of erythropoietin (EPO) signaling pathway in the absence of Fyn. Indeed, 
in Fyn-/- erythroblasts we observed a reduction in Tyr-phosphorylation state of EPO-
R associated with a compensatory activation of Jak2 without major change in Lyn 
activity. A reduction in STAT5 activation resulting in down-regulation of Cish, a 
known direct STAT5 target gene, was noted in Fyn-/- erythroblasts. This was 
paralleled by a reduction in GATA1 and increased HSP70 nuclear translocation 
compared to wild type, supporting a higher cellular pro-oxidant environment in the 
absence of Fyn. Using the vitro cell forming colony unit assay, we found a lower in 
 2 
CFU-E and BFU-E cells production, which once again was associated with 
decreased activation of EPO mediated cascade in the absence of Fyn. To explore 
the possible role of Fyn in stress erythropoiesis, mice were treated with either 
phenylhydrazine (PHZ) or doxorubicin (Doxo). Fyn-/- mice showed prolonged anemia 
after either PHZ or Doxo treatment with a delayed hematologic recovery compared 
to wild-type animals. When we analyzed the expression of a battery of ARE-genes 
related to oxidative response such as catalase, Gpx, heme-oxygenase 1 and 
peroxiredoxin-2, we noted up-regulated expression of these genes in sorted Fyn-/- 
erythroblasts compared to wild-type cells. In agreement, we observed increased 
activation of the redox-sensitive transcriptional factor Nrf2 targeting ARE-genes, 
whose regulation has been previously linked to Fyn. In fact, Nrf2 is switched-off by 
Fyn, ubiquitylated and delivered to the autophagosome by the p62 cargo protein. In 
Fyn-/- sorted erythroblasts, we observed (i) accumulation of p62 in large clusters; and 
(ii) reduction of Nrf2-p62 complex compared to wild-type cells. To address the 
question whether the perturbation of Nrf2-p62 system results in impairment of 
autophagy in the absence of Fyn, we used Lysotrack to explore late phases of 
autophagy. Lysosomal progression was defective in Fyn-/- reticulocytes and it was 
associated with accumulation of p62 during in vitro reticulocyte maturation. These 
data indicate that the absence of Fyn blocks the Nrf2 post-induction response to 
oxidation, resulting in impaired autophagy. To validate our working hypothesis, we 
treated Fyn-/- mice with Rapamycin, an inducer of autophagy. In Fyn-/- mice, 
Rapamycin treatment resulted in decrease dyserythropoiesis, ROS levels and 
Annexin V+ cells, associated with reduction in accumulation of p62 in Fyn-/- 
erythroblasts. As a proof of concept, we treated both mouse strains with PHZ with or 
without Rapamycin. This latter worsened PHZ induced acute anemia in wild-type 
mice but not in Fyn-/- animals.  Collectively, our data enabled us to document a novel 
role for Fyn in erythropoiesis, contributing to EPO-R activation and harmonizing the 
Nrf2-p62 adaptive cellular response against oxidation during normal and more 
importantly in stress erythropoiesis.  
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β-thalassemia (β-thal) is one of the most common monogenetic disorders 
worldwide, characterized by ineffective erythropoiesis leading to a chronic, 
debilitating anemia associated with high morbidity and mortality. Erythroid 
maturation is a dynamic process tightly regulated by complex signaling 
mechanisms, only partially described either in normal and diseased erythropoiesis. 
To investigate this issue, we carried out a high throughput kinome analysis by 
taking advantage of Kinexus array technology (http://www.kinexus.ca), in sorted 
erythroid precursors from mouse model of (Hbb3th/+) compared to wildtype animals.  
In β-thal mice, we found differential modulation of many protein kinases. Network 
computational analysis unveiled common as well as erythroid precursor-specific 
signaling mechanisms of altered erythrocyte differentiation in beta thalassemia, 
suggesting a selective perturbation in protein kinase/phosphatase balance in β-thal 
erythropoiesis.   
We reasoned that balancing kinome anomalies, by increasing phosphatome activity, 
could normalize kinome signaling pathways, thus ameliorating erythropoiesis. We 
explore the expression and function of different protein phosphatase and we found 
reduced expression and function of protein Tyr-phosphatase receptor type, gamma 
(PTPRG). To investigate PTPRG role in erythropoiesis, we exploited a novel Trojan-
fusion protein (TAT-ICD) we recently patented that delivers intracellularly the 
catalytic domain of PTPRG and up-modulates its signaling cascade, as both a 
research tool to map dysfunctional pathways and as a potential therapeutic agent. 
In β-thal mice, TAT-ICD acted on multiple abnormally activated targets identified by 
computational analysis. TAT-ICD significantly reduced the activation of (i) Jak2- 
STAT5 pathway; (ii) Bruton tyrosine kinase (BTK) that has been reported to be part 
of the erythropoietin cascade; (iii) Akt that is involved in TGF-b-smad signaling 
pathway. This was associated with down-regulation of Erfe and Gdf11 gene 
expression in sorted erythroblasts from TAT-ICD treated β-thal mice. Collectively, 
TAT-ICD treatment resulted in amelioration of β-thal ineffective erythropoiesis, 
evaluated by  multiple approaches, including the profile of erythroid maturation and 
the amount of Annexin-V+erythroid cells, reticulocyte count, circulating erythroblasts 
and hemolytic indices (U.S. Patent #62/109,555). The improvement of anemia was 
also associated with reduction in alpha aggregates and membrane bound 
hemichromes in circulating erythrocytes. We also found a reduction of liver and 
spleen iron accumulation in agreement with the beneficial effects on the 
hematologic phenotype.  It is of note that TAT-ICD treatment did not affect either 
peripheral leukocyte counts or spleen lymphocyte pattern.  
Our data unveil abnormalities in signal transduction pathways as new mechanism 
involved in β-thal erythropoiesis, and validate a novel, breakthrough, therapeutic 
approach to reset back to homeostatic equilibrium altered kinome in diseased 
erythropoiesis.  
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The unbalanced hemoglobin chain synthesis in beta-thalassemias leads to hemichrome-
induced damage that contributes to ineffective erythropoiesis, hemolysis and reduced red 
cell survival. Iron overload related to ineffective erythropoiesis and abnormally low 
Hepcidin (Hamp), combined with the cytotoxic effects of free heme with free-alpha-chains 
play a key role in the increased generation of reactive oxygen species (ROS) in beta 
thalassemias.[2][HA{3] Here we used a specific and selective inhibitor of the plasma 
membrane expressed glycine transporter GlyT1 (Ro4917838). Use of Ro4917838 has 
been associated with a dose-dependent decrease in MCH, Hb, soluble transferrin 
receptor, and increase in absolute reticulocytes and RBC counts in several animal 
species, attributed to reduce glycine bioavailability in erythroblasts and decreased heme 
synthesis. In rats, Ro4917838 reduces heme synthesis, and down-regulates erythroid 
transferrin receptor, but does not interfere with hepcidin regulation and systemic iron 
homeostasis (Winter et al. Exp Hematol, DOI: 10.1016/j.exphem.2016.07.003). We aimed 
to determine if reduced cellular availability of glycine in erythroblasts may reduce heme 
synthesis, and impact pathologic erythropoiesis in a mouse model for b-thalassemia. Wild-
type control (WT) C57B6/2J, and beta-thalassemia Hbbth3/+ mice were treated with either 
vehicle or Ro4917838 at dosages of 3, 10, 30 mg/kg/d administered over 4 weeks once 
daily by gavage. [6]RO4917838 administration was associated with significant 
improvements of central hallmarks of the b-thalassemia pathology. Reduced erythrocyte 
destruction was seen bydemonstrated by [8][WM{9]as significant improvements in 
erythrocyte morphology and amelioration of hemoglobin reduction in reticulocytes. We also 
observed an impressively quick reduction of the circulating erythroblast count within 1 
week of initiating treatment. This was also associated with decreased hemolysis 
biomarkers. Ro4917838 induced a significant reduction in extramedullary erythropoiesis 
and reduction in orthochromatic erythroblasts as well as insoluble alpha chain aggregates 
in circulating red cells. Red cell survival of b-thal mice treated with 30 mg/kg/day 
Ro4917838 significantly increased by more than 50%. CD71+ erythroid precursors 
significantly decreased in WT mice treated with Ro4917838 at 30 mg/kg and in b-thal mice 
at the dosage of 30 mg/kg/ d. [10]These data suggest that Ro4917838 ameliorates anemia 
in a b-thalassemia mouse model and positively affects ineffective erythropoiesis and red 
cell survival in peripheral circulation. Ro4917838 may represent a novel therapeutic 
approach for the treatment of anemia in b-thalassemia patients. [1] I do see the point for 
beta-thalassemia, but this does not apply for all thalassemias, I mean the free alpha 
chains. The ROS yes, they have in common. In this sentence it seems to be that the alpha 
chains are culprit for ROS in all thalassemias. [HA{3]I do see the point for beta-
thalassemia, but this does not apply for all thalassemias, I mean the free alpha chains. 
The ROS yes, they have in common. In this sentence it seems to be that the alpha chains 
are culprit for ROS in all thalassemias. ROS was not measured, therefore I would refrain 
mentioning it. No data is shown. [HA{5]ROS was not measured, therefore I would refrain 
mentioning it. No data is shown. I propose deletion of the PK info. Although the information 
is correct I don’t think this is the level of detail needed for the abstract. It may even be 
confusing as it is not the focus of the abstract to do a cross species comparison. [AK7]I 
propose deletion of the PK info. Although the information is correct I don’t think this is the 
level of detail needed for the abstract. It may even be confusing as it is not the focus of the 
abstract to do a cross species comparison. Dosing and dosing frequency is already 
described above, we do not need to repeat this here. [WM{9]Dosing and dosing frequency 
is already described above, we do not need to repeat this here. Was the liver expression 
determined or the serum Hepcidin levels measured? I would rephrase it if latter is the 
case. [HA{11]Was the liver expression determined or the serum Hepcidin levels 
measured? I would rephrase it if latter is the case. 
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THE PYRUVATE KINASE ACTIVATOR AG-348 IMPROVES MURINE Β-THALASSEMIC ANEMIA AND CORRECTS
INEFFECTIVE ERYTHROPOIESIS
alessandro matte1, elisabetta beneduce1, angela siciliano1, penelope kosinski2, anne janin3, christophe lebouef3, achille
iolascon4, luigia de falco4, lenny dang2, charles kung2, Lucia De Franceschi* 1
1medicine, University of Verona, verona, Italy, 2development, agios, Cambridge, United States, 3pathology, universite,
Paris, France, 4ceinge, University, naples, Italy
Background: β-thalassemias (β-thal) are worldwide distributed red cell disorders, characterized by ineffective
erythropoiesis and reduced red blood cell (RBC) lifespan. Increased levels of reactive oxygen species (ROS) have been
reported to play a key role in anemia of β thal, targeting both erythropoiesis and circulating RBCs. Pyruvate kinase (PK)
is an important enzyme in the glycolytic pathway, responsible for conversion of phosphoenolpyruvate to pyruvate, with
concomitant formation of the energy carrier adenosine triphosphate (ATP).  As mature erythrocytes lack mitochondria,
they rely almost exclusively on glycolysis to generate ATP, as well as the interlinked pentose phosphate pathway shunt to
generate the reducing agent NADPH.   The possible impact of PK activity on erythropoiesis is supported by evidence of
ineffective erythropoiesis in human subjects with PK deficiency as well as mouse models of PK deficiency. The PK
activator AG-348 has been evaluated in Phase I trials in healthy human subjects (NCT02149966) and is currently in
Phase II studies in PK deficiency patients (NCT02476916).  In the Phase I studies, AG-348 was shown to decrease
levels of an upstream metabolite 2,3-diphosphoglycerate (2,3-DPG) and increased levels of ATP in  whole blood,
consistent with in vivo activation of PK.
Aims: To evaluate the impact of AG-348 on anemia and ineffective erythropoiesis in a mouse model of β thal intermedia. 
Methods:  Mouse strains C57B6/2J, as wildtype (WT) controls, and Hbbth3/+, as a mouse model of β-thal intermedia, were
used. Female mice aged between 2-3 months were treated with either vehicle or AG-348 at 50 mg/kg bid by oral gavage.
Hematologic parameters, RBC indices, morphology, and reticulocyte count were evaluated at baseline, 7, 14, 21 days of
treatment. Mouse erythropoiesis was studied using the CD44/TER119 gating strategy by FACS. ROS levels and the
amount of Annexin-V+ cells were evaluated in erythroblast populations.  Liver iron accumulation was evaluated by Pearl’s
staining and expression of liver hepcidin was measured by RT-PCR.  
Results:  In Hbb3th/+ mice, 21 days of AG-348 treatment was associated with (i) a marked amelioration of
anisopoykylocytosis; (ii) significantly increased Hb levels, MCV and MCH; (iii) a significant reduction in circulating
erythroblasts (Es) and reticulocyte count; and (iv) reduction of ROS levels in circulating RBCs. In addition, AG-348
significantly decreased the amount of membrane precipitated α-globin chains and increased the amount of soluble Hb
compared to the vehicle treated Hbb3th/+ group. Consistent with these findings, we observed (i) a reduction of
extramedullar erythropoiesis as indicated by both a decrease in spleen weight/mouse weight ratio and total Es
(CD44TER119 Fsc high cells); (ii) a significant increase in pro-Es and basophilic Es, associated with reduction in
orthochromatic Es; (iii) a reduction in ROS levels of Hbb3th/+ Es and the amount of apoptotic orthochromatic Es compared
to vehicle treated Hbb3th/+ mice, suggesting an amelioration of β thal ineffective erythropoiesis.. The amelioration of
ineffective erythropoiesis was paralleled by a reduction in liver iron overload and up-regulation of hepcidin mRNA in liver
from AG-348 treated Hbb3th/+ mice.
 
Summary/Conclusion: Our data show that the PK activator AG-348 beneficially affects ineffective erythropoiesis in a
mouse model of β thal and might represent a novel therapeutic tool in clinical management of anemia in β thalassemic
syndromes.      
Keywords: Red blood cell, Thalassemia
Fyn plays a novel key role in erythropoiesis as oxidative sensor  
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Background 
Fyn is a member of the Src family of tyrosine kinases (SFKs) and shares high homology with Lyn that has been 
previously involved in erythropoiesis. Previous reports have shown that Lyn targets EPO-R/Jak2/STAT5 signaling 
pathway. Although progresses have been done in the knowledge of molecular mechanisms involved in normal and 
diseased erythropoiesis, much still remains to be investigated on signal transduction pathway during erythroid 
differentiation and maturation.  
Aims 
Functional characterization of erythropoiesis in Fyn
-/- 
mice. 
Methods 
Female aged between 2-4 months from C57BL/6J, as wild-type (WT) controls, and Fyn
-/- 
mouse strains were used. 
Phenylhydrazine (PHZ) at 40 mg/kg or Doxorubicin at 0,25mg/kg by intraperitoneal injection were used to explore 
stress erythropoiesis. Hematologic parameters, red indices and reticulocyte count were evaluated as previously 
reported (Matte A, et al. ARS, 2015). Mouse erythropoiesis was studied using the CD44/Ter119 gating strategy by 
FACS. ROS levels and the amount of Annexin V
+
 cells were also evaluated in erythroblast subpopulations. In vitro 
colony-forming unit assay was performed to obtain CFU-Es and BFU-Es. Immunoblot analysis was carried out to 
study early and late erythropoiesis.  
Results 
Fyn
-/-
 mice showed signs of dyserythropoiesis associated with increased total erythroblasts (CD44
+
TER119
+
FSC
high
), 
without extramedullar erythropoiesis. Fyn
-/-
 erythroblasts showed higher ROS levels and increased amount of 
Annexin V
+
 cells, compared to WT, indicating increase oxidative stress and cell aptoptosis. High ROS levels in 
erythroblasts have been described in β-thalassemic mouse erythroid cells as model of stress erythropoiesis. This has 
been linked with instability of GATA-1, which nuclear translocation is prevented and requires the stabilization of heat 
shock protein (HSP70-90). In Fyn
-/-
 mice, we explored GATA-1/HSP70 distribution in subcellular fractions. Fyn
-/-
 
erythroblasts showed reduction in GATA-1 nuclear translocation, compared to WT. In agreement with reduced GATA-
1 nuclear translocation, a marked decrease in β–globin chain synthesis, resulting in an imbalance in α/β globin chain 
levels, was observed in Fyn
-/-
 mice.  
To further characterize the impact of the absence of Fyn on erythropoiesis, we set up a colony-forming unit assay for 
CFU-E and BFU-E. The lack of Fyn resulted in a significant decrease in CFU-E and BFU-E colonies, suggesting an 
impairment of early erythropoiesis. Erythroid commitment and differentiation is strictly dependent on EPO-
R/Jak2/STAT5 signaling pathway. The absence of Fyn resulted in a marked decrease in STAT5 activation, supported 
by a significant down-regulation of Cish, that is strictly regulated by STAT5 function. 
Using Doxorubicin and PHZ, we found a delay in increased reticulocyte count related to either Doxorubicin or PHZ 
treatment, shedding new light on the role of Fyn in stress erythropoiesis.  
In addition, we found chronic activation of Nrf2 related to lack of its physiologic inhibitor, Fyn. Indeed, we found 
increased ARE-related genes such as heme oxygenase-1 (HO-1), which  expression seems to became independent 
from heme concentration in the absence of Fyn. In fact, bilverdin reductase (BVR) that is functionally link to Nrf2 but it 
depends from another transcriptional factor was similar to that observed in WT mice.  
Conclusions 
Our preliminary data support a novel role of Fyn as both oxidative sensor and new modulator of the EPO/STAT5 
pathway. 
 
